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Abstract 26 
Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them being 27 
approved for the treatment of HIV (tenofovir), chronic hepatitis B infections (tenofovir and adefovir) or human 28 
cytomegalovirus retinitis (cidofovir). In addition, cidofovir is mostly used off-label for the treatment of viral 29 
infections caused by several DNA viruses other than cytomegalovirus, including papilloma- and polyomaviruses, 30 
which do not encode for their own DNA polymerases. There is considerable interest in understanding why 31 
cidofovir is effective against these small DNA tumor viruses. Considering that papilloma- and polyomaviruses 32 
cause diseases associated either with productive infection (characterized by high production of infectious virus) 33 
or transformation (where only a limited number of viral proteins are expressed without synthesis of viral 34 
particles), it can be envisaged that cidofovir may act as antiviral and/or antiproliferative agent. 35 
The aim of this review is to discuss the advances performed during the last years in understanding the mode 36 
of action of ANPs as antiproliferative agents giving the fact that current data suggest that their use can be 37 
extended for the treatment of non-viral related malignancies. 38 
 39 
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1. Introduction 94 
The acyclic nucleotide analogue cidofovir {(CDV), 1-[(S)-3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine, 95 
HPMPC}, displays potent activity against a broad spectrum of DNA viruses. The intravenous formulation of CDV 96 
has been formerly licensed for the treatment of human cytomegalovirus (HCMV) retinitis in AIDS patients in 97 
1996. However, this compound is mostly used off-label for the treatment of severe infections caused by various 98 
DNA viruses other than HCMV (De Clercq, 2007,De Clercq, 2011). Different formulations of CDV have been 99 
employed for the management of acyclovir resistant and/or foscavir resistant herpes simplex virus infections, 100 
poxvirus-associated diseases including molluscum contagiosum virus and orf virus, life-threatening adenovirus 101 
and human polyomavirus (PyV) infections as well as human papillomavirus (HPV)-associated hyperproliferative 102 
diseases. A summary of the applications of CDV as an antiviral and antiproliferative agent in the treatment of 103 
human diseases is presented in Table 1. 104 
CDV belongs to the class of acyclic nucleoside phosphonates (ANPs), which are well-known for their antiviral 105 
properties. In addition to CDV, two other ANPs got approval for the treatment of viral infections (De Clercq and 106 
Holy, 2005,De Clercq, 2007,De Clercq, 2006). Tenofovir {PMPA, (R)-9-[2-(phosphonylmethoxy)propyl]adenine} 107 
and adefovir {PMEA, 9-[(2-phosphonylmethoxy)ethyl]adenine} are active against retro- and hepadnaviruses, 108 
their oral prodrugs forms being licensed for the therapy of human immune deficiency virus (HIV) (tenofovir) and 109 
of chronic hepatitis B virus (HBV) infections (tenofovir and adefovir).  110 
ANPs have been shown to enter the cell by an endocytosis-like process and they are converted intracellularly 111 
to their diphosphate metabolites by cellular enzymes (De Clercq and Holy, 2005). The diphosphate forms of the 112 
ANPs (i.e. CDVpp, PMEApp and PMPApp) interact as competitive inhibitors/alternative substrates with respect 113 
to the normal substrates (i.e. dCTP and dATP). Incorporation of one molecule of PMEApp or PMPApp into the 114 
growing DNA strand results inevitably in DNA chain termination whereas CDVpp requires two consecutive 115 
incorporations to efficiently terminate DNA synthesis, as has been shown for HCMV (Xiong et al., 1996,Xiong et 116 
al., 1997). The selective antiviral activity of ANPs results from the higher affinity of the ANPpp for viral DNA 117 
polymerases [that is herpesvirus and poxvirus DNA polymerases and HIV or HBV reverse transcriptases] than for 118 
cellular DNA polymerases α, δ, and ε. Figure 1 illustrates the intracellular activation of CDV and its mode of 119 
action against viruses encoding for their own DNA polymerases. The mechanism of action of ANPs as antiviral 120 
agents has been extensively summarized in various reviews (De Clercq, 2003,Andrei and Snoeck, 2010,De Clercq, 121 
2007,De Clercq, 2011,De Clercq and Holy, 2005) and will not be further discussed here. 122 
Besides their well-recognized antiviral characteristics, CDV as well as some PME derivatives, such as PMEA, 123 
PMEDAP  {9-[(2-phosphonylmethoxy)ethyl]-2,6-diaminopurine} and PMEG {9-[(2-124 
phosphonylmethoxy)ethyl]guanine} (Figure 2), possess antiproliferative properties, although their mechanisms 125 
of antitumor efficacy appear to be dissimilar considering that CDV is not an obligate chain terminator, in 126 
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contrast to the PME derivatives, and that the effects of CDVpp on cellular DNA polymerization are weaker 127 
compared to the diphosphate forms of the PME derivatives (Wolfgang et al., 2009). 128 
In this review, we focus on the antiproliferative activities of ANPs and we debate on their mode of action 129 
against viruses, such as polyomaviruses (PyVs) and papillomaviruses (PVs) that do not encode for their own DNA 130 
polymerases. Also, the potential use of ANPs for the treatment of non-viral induced tumors will be discussed.   131 
   132 
2. Similarities and differences between polyomaviruses (PyVs) and papillomaviruses (PVs) 133 
Until 2000, PVs and PyVs were grouped together in the family Papovaviridae (“pa-po-va” stands for 134 
papilloma- polyoma – vacuolizing agent SV40). Since then, the family Papovaviridae is obsolete and the 135 
Papillomaviridae and Polyomaviridae families were recognized by the International Committee on Taxonomy of 136 
Viruses (ICTV) (Johne et al., 2011,de Villiers et al., 2004)  137 
Table 2 summarizes the main similarities and differences between PyVs and PVs. These two viral families 138 
have a non-enveloped icosahedral capsid (composed of 72 capsomers) surrounding a double-stranded circular 139 
DNA genome of ∼5kbp in PyVs and of ∼8kbp in PVs.  Both viruses use overlapping genes and differential splicing 140 
to pack the maximum amount of genetic material in the minimum space. All open reading frames (ORFs) are 141 
located on only one (PVs) or both (PyVs) strands of DNA, as depicted in Box 1 and Box 2, respectively. Two 142 
classes of genes, the early (E) genes (which are required for viral DNA replication) and late (L) genes (coding for 143 
the structural proteins) exist in both PyVs and PVs. 144 
The HPV genome contains a coding region that encompasses an E region that includes up to seven ORFs 145 
encoding non-structural proteins and the late region comprises the L1 and L2 ORFs. In HPV, a ∼1kbp non-coding 146 
region [also known as the long control region (LCR) or the upstream regulatory region] separates the early and 147 
late regions. The LCR harbours the origin of replication, the transcription start sites and promoter/enhancer 148 
elements that regulate viral gene expression.  In PyV, both strands of DNA code for the viral proteins. One strand 149 
of DNA encodes an overlapping set of multifunctional early regulatory proteins and the other strand encode for 150 
the capsid proteins expressed late in permissive cells. Some PyVs also encode for an agno protein that facilitates 151 
virion assembly. The control region between the early and the late transcription units contains a bidirectional 152 
enhancer, early and late promoters, the viral origin of replication, the viral packaging signal and binding sites for 153 
host transcription factors. 154 
Papillomavirus particles are ∼55 nm diameter, compared to ∼45 nm diameter in PyVs. Papillomaviruses 155 
encode two structural proteins: the major capsid protein, L1 (∼510 amino acids and ∼58 kDa), and the minor 156 
protein L2 (∼470 amino acids and ∼51 kDa). In contrast, PyVs encode for three structural proteins: the major 157 
capsid protein, VP1 (∼370 amino acids and ∼41 kDa) and two minor proteins VP2 (∼350 amino acids and ∼38 158 
kDa) and VP3 (∼230 amino acids and ∼26 kDa). Despite significant differences in amino acid sequences of the 159 
major capsid proteins, both PV and PyV capsids exhibit conserved features, as the 72 capsomers are pentamers 160 
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of the major capsid protein and are arranged on a T=7 icosahedral lattice. Papillomaviridae and Polyomaviridae 161 
differ in capsomer morphology and size. Papillomavirus capsomers are star-shaped, 11 to 12 nm in diameter, 162 
while polyomavirus are barrel-shaped, 8 nm in diameter. Intercapsomer interactions are also slightly different 163 
between these viral families (Belnap et al., 1996). The carboxyl terminus of VP1 or L1 mediates contacts 164 
between the pentamers in the capsid. While disulfite bonds stabilize the interpentamer contacts for L1, both 165 
disulfite bonds and calcium bridges stabilize these contacts for VP1 (Sapp and Day, 2009). Also, differences in 166 
receptor binding and internalization pathway also exist between PVs and PyVs, reviewed in (Sapp and Day, 167 
2009). 168 
Polyomaviruses generally have a narrow host range and limited cell type tropism (Gjoerup and Chang, 2010). 169 
In their natural host, they are able to infect cells giving rise to a productive life cycle causing cell lysis. In 170 
addition, PyVs establish a latent/persistent infection that is asymptomatic and is rarely associated with disease 171 
unless when the immune system is impaired. The full, infectious viral life cycle of human PyVs has only been 172 
studied for JCPyV and BKPyV because no infectious system exists up to now for the other human PyVs (Box 3). 173 
As PyVs are non-enveloped viruses, the viral capsid proteins interact directly with the receptor molecules in 174 
order to gain entry into the cells, being this interaction a major determinant of host and tissue tropism. Entry of 175 
PyVs into the cells includes receptor binding, internalization and intracellular trafficking, virus uncoating and 176 
nuclear entry. Once the uncoated viral genome is inside the cells, the regulatory early proteins [Large tumor 177 
antigen (LT-ag) and small T antigen (sT-ag) are produced in all PyVs. Besides LT-ag and sT-ag, other virus-specific 178 
T-antigen isoforms [such as middle T antigen (mT-ag) in rodent PyVs, the 17kT antigen in SV40 and the 57kT 179 
antigen in Merkel cell polyomavirus (MCPyV)] are derived from alternative splicing of the LT-ag transcript (Cheng 180 
et al., 2009,An et al., 2012,Topalis et al., 2013). Some PyVs can cause tumors and products from the early region, 181 
especially SV40 LT-ag and murine PyV mT-ag, are required for cellular transformation.  182 
In benign lesions induced by PyVs, viral genomes are typically maintained extra-chromosomally. Malignant 183 
progression, as in the case of Merkel cell carcinoma (MCC), is associated with viral integration into host cell 184 
chromatin (Box 1).  Although MCPyV is very common, MCC is very infrequent, most probably because 185 
integration is not part of the MCPyV life cycle and is a rare event. This integration event is involved in the 186 
initiation of the tumor, since MCPyV was found to be clonally integrated into a single site of the host genome, 187 
indicating that viral integration preceded tumor expansion (Feng et al., 2008,DeCaprio and Garcea, 2013). 188 
Recently, an overprinting gene, expressed from an Alternate Frame of the Large T Open reading frame (ALTO) 189 
was identified in MCPyV (Carter et al., 2013). Although ALTO is expressed during replication of MCPyV genome it 190 
is not required for replication. Despite no sequence similarities with the rodent mT-Ag, ALTO was found to be 191 
evolutionary related to mT-ag. 192 
Both PyV and PVs multiply in the nucleus of the infected cell and their circular genome associates with host 193 
encoded histones in the virions. These small DNA tumor viruses widely rely on the host cell DNA replication 194 
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machinery to replicate their genomes.  The LT-ag in PyVs is a multifunctional initiator protein that can 195 
successively recognize the viral origin of replication, assemble into a double hexamer melting and unwinding the 196 
DNA ahead of the replication fork, and interact with the host DNA replication factors (such as polymerase α-197 
primase, replication protein A (RPA) and topoisomerase I (Box 4). The LT-ag also contains several intrinsic 198 
biochemical activities and binds to several cellular proteins, directing the cellular machinery to support viral 199 
replication. LT-ag interacts with heat shock protein 70 (Hsc70) through its DnaJ domain and with members of the 200 
retinoblastoma (Rb) family of pocket proteins (i.e. pRB, p107, and p130) through the LXCXE motif in its N-201 
terminal region. Binding of LT-ag to the Rb family of proteins impairs their role as repressor of E2F transcription 202 
factors promoting transition into S-phase of the cell cycle (Box 5). LT-ag also interacts with the tumor suppressor 203 
protein p53 and functionally inactivates its ability to induce cellular senescence or apoptosis in response to DNA 204 
damage (Cheng et al., 2009,Topalis et al., 2013,An et al., 2012). Thus, the LT-ag has pleiotropic functions, 205 
including initiation and maintenance of viral DNA replication, regulation of early and late genes transcription, 206 
virion assembly and manipulation of the host cell cycle through a number of protein-protein interactions. The 207 
LT-ag has also been shown to induce transformation and immortalization in different in vitro and in vivo models 208 
which can be attributed, in part, to the ability to inactivate the tumor suppressor proteins p53 and pRb.   209 
The LT-ag is such a multifunctional protein that the immediate targets of interaction with host cell regulatory 210 
proteins are very difficult to unleash, even with experimental site-directed mutagenesis of this very large, multi-211 
domain viral protein that forms 12 subunit homo-complexes as well as diverse hetero-complexes with various 212 
host proteins.  Papillomaviruses carry out virtually the same interactions with the host cell as do PyVs, although 213 
PVs do so by using separate gene products. Therefore, the targets and functions of HPV early proteins (i.e. E6, 214 
E7, E1, and E2) are far more assignable than they are with large T-ag, which incorporates all these functions. 215 
Another source of misinformation when comparing PyVs with PVs is that almost all the biology of the PyVs has 216 
been studied using immortalized cell lines grown in monolayers, and many important interactions have been 217 
missed because the cells are constitutively activated for pathways normally targeted for activation (or 218 
suppression) by the viruses in living host organisms. 219 
LT-ag is indispensable for PyV DNA replication which begins when two hexamers of the LT-ag are formed in a 220 
head-to-head orientation at the origin of replication. Most organisms have a replicative DNA helicase that 221 
unwinds DNA as a single hexamer that encircles and translocates along one strand of the duplex DNA and 222 
excludes the complementary strand (known as steric exclusion). It has been a matter of debate whether a single 223 
or a double hexamer of LT-ag encircles and acts on single-stranded DNA or double-stranded DNA during 224 
unwinding. A recent study has clearly shown that a double hexamer of LT-ag assembles at replication origin, and 225 
then separates into two single hexamers and each hexamer unwinds dsDNA by encircling and translocating 226 
along each ssDNA in the 3’- to -5’ direction (Box 4) (Yardimci et al., 2012). Furthermore, the authors described 227 
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the surprising ability of the LT-ag to overcome molecular barriers in its path by transiently opening its ring. This 228 
highlights the remarkable plasticity of hexameric structures. 229 
Following recognition and binding to the origin of replication, melting of the DNA helix surrounding the 230 
origin, and oligomerization into two hexamers at the origin of replication, the LT-ag then recruits the cellular 231 
DNA replication factors: RPA, topoisomerase I and polymerase α primase. Type I topoisomerases are essential to 232 
relieve supercoiling stress as the strands unwind (Lin et al., 2002). Podophyllotoxin (Condylox) is a 233 
topoisomerase I inhibitor in clinical use against HPV lesions to block viral DNA replication (Stern et al., 2012). As 234 
podophyllotoxin is also active against host chromosomal replication, it is cytotoxic. Following the initiation 235 
events, the clamp loader, replication factor C (RFC), and the polymerase processivity factor, PCNA (proliferating 236 
cell nuclear antigen), are recruited and loaded leading to the binding and activity of DNA polymerase δ, which 237 
extends both lagging and leading strands. After PyV DNA replication and the expression of late structural 238 
proteins, new progeny virions are assembled and are released from the infected cell. 239 
Papillomaviruses are highly diverse and have been discovered in a wide array of vertebrates and their host 240 
range include all amniotes (Rector and Van Ranst, 2013). Papillomaviruses are highly host-restricted, and cause 241 
abortive infections in non-host species. The HPV life cycle is closely linked to the differentiation state of the 242 
epithelial cells and the initial step involves the infection of keratinocytes in the basal layer of squamous epithelia 243 
(Box 6) (Stanley, 2012,Chow et al., 2010,Duensing and Munger, 2004,zur Hausen H., 2002).  Similarly to PyVs, 244 
HPVs do not encode for their own DNA polymerases but they encode for viral proteins (i.e. E1 and E2) that are 245 
required for viral genome replication during the HPV productive cycle (Box 7). (D'Abramo and Archambault, 246 
2011,McBride, 2013,Bergvall et al., 2013).  E1 is the most highly conserved HPV protein and the only one with 247 
enzymatic activity. E1 is the replicative helicase of HPV and is essential for viral replication and pathogenesis. 248 
Both LT-ag and the E1 protein are structurally related members of the helicase superfamily III (SF3).  E1 binds to 249 
the origin of replication together with E2 protein. In fact, the E2 protein assists and directs faithful viral origin 250 
recognition of E1 while E1 is the replicative DNA helicase, melting the DNA around the origin of replication and 251 
establishing itself as a double hexameric helicase. The formation of the E1-E2-origin of replication complex 252 
involves not only the binding of E1 and E2 to specific viral DNA elements in the origin of replication but also a 253 
protein-protein interaction between the N-terminal transactivation domain of E2 and the helicase/ATPase 254 
domain of E1 (Box 7). Similar to LT-ag, E1 also acts to recruit the cellular DNA replication proteins to the PV DNA 255 
replication fork.  256 
HPV E6 and E7 genes encode low molecular weight proteins of about, respectively, 150 and 100 amino acids 257 
(Box 8). It has been shown that expression of E6 and E7 from high-risk HPV types is necessary and sufficient to 258 
immortalize primary keratinocytes, abrogates DNA damage responses, causes genomic instability, and induces 259 
epithelial cell hyperplasia (Ghittoni et al., 2010,Hellner and Munger, 2011,Moody and Laimins, 2010). HPV E6 260 
and E7 proteins do not have intrinsic enzymatic activity but function by associating with several cellular proteins 261 
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resulting in the alteration of various host cellular pathways. Specific interactions of E6 and E7 with key cell cycle 262 
regulatory proteins [namely E6 with the tumor suppressor protein p53 and E7 with the Rb family of pocket 263 
proteins] are responsible for the potential oncogenicity of the high-risk HPV types (Box 9). An important function 264 
of p53 is to induce the expression of genes that alter cell cycle progression in G1/S phase in response to DNA 265 
damage. Crucial host cell targets of the high-risk E6 protein include many PDZ domain-containing proteins 266 
involved in cell-cell contact, communication and polarity (Howie et al., 2009). The Rb family of proteins control 267 
the transition at the G1/S phase of the cell cycle by binding and regulating the activity of the E2F family of 268 
transcription factors. As a consequence of these interactions, E7 stimulates quiescent cells to re-enter S-phase 269 
while E6 prevents cellular growth arrest or DNA-damage induced apoptosis (Box 9).  270 
In contrast to PyV LT-ag that inactivates Rb/E2F complexes by stoichiometric association with Rb, high-risk 271 
HPV E6 and E7 proteins target, respectively, p53 and Rb for ubiquitin-mediated proteosomal degradation (Pim 272 
and Banks, 2010,McLaughlin-Drubin and Munger, 2009,Yugawa and Kiyono, 2009,Moody and Laimins, 273 
2010,Miller et al., 2012). E6 associates with the cellular E3 ubiquitin ligase E6-associated protein (E6AP) and the 274 
E6/E6AP complex binds p53 and induces its specific ubiquitinylation and subsequent degradation by the 275 
proteasome (Box 9). High-risk HPV E7 mediates degradation of Rb by a mechanism involving association with 276 
and reprogramming of the cullin 2 (CUL2) ubiquitin ligase complex, resulting in the release of active E2F 277 
transcription factor which in turn activates the transcription of genes encoding proteins (such as cyclin E and 278 
cyclin A) necessary for cell cycle progression (Box 9).  279 
One member of the RB family, p130, appears to be an important target for E7 in promoting its proteosome-280 
mediated destruction and S-phase entry. Recent evidence indicates that p130 regulates cell-cycle progression as 281 
part of a large complex named DREAM (DP, Rb-like, E2F and MuvB). In addition, it was demonstrated that high-282 
risk HPVs can bind to MuvB core complex and activate gene expression during the G2 and M-phase of the cell 283 
cycle. Thus, high-risk HPV E7 perturbs the DREAM complex to prevent exit from the cell cycle entry and also to 284 
promote cellular proliferation and mitotic gene expression (DeCaprio, 2014,Banerjee et al., 2011,Nor et al., 285 
2013,Nor et al., 2011). 286 
E4 and E5 proteins contribute indirectly to genome amplification success because they modify the cellular 287 
environment.  E5 is a small transmembrane protein with a cytoplasmatic C-terminus (Box 8). It is thought to 288 
function by inducing ligand-independent dimerization and activation of receptor protein tyrosine kinases, 289 
including the epidermal growth factor receptor (EGFR) (DiMaio and Petti, 2013). Hence, E5 contributes to 290 
genome amplification success through its ability to stabilize EGFR and its role in up-regulation of mitogenic signal 291 
transduction. Many but not all HPVs encode for E5, and this viral oncoprotein contributes to some early steps of 292 
viral transformation but it is not necessary for malignant progression and/or maintenance of the transformed 293 
phenotype since E5 is not generally expressed in cervical carcinomas. While bovine papillomavirus (BPV)-1 E5 294 
protein interacts with PDGF (platelet derived growth factor), this is not an activity of the HPV E5 protein. BPV-1 295 
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E5 protein (which functions as a disulfide cross-linked dimer) is phylogenetically unrelated to the E5 proteins of 296 
alpha group HPV types (which form hexameric transmembrane pores, placing it within the virus-encoded 297 
“viroporin” family). It was found that high-risk human papillomavirus E5 oncoprotein displays channel-forming 298 
activity sensitive to small-molecule inhibitors (Wetherill et al., 2012). 299 
The productive phase of the HPV life cycle occurs in the terminally differentiated layers of the stratified 300 
epithelium, where viral particles are assembled and shed. Differentiation of infected cells induces genome 301 
amplification and a remarkable increase in late gene expression resulting in packaging of the viral genome and 302 
virus release (Doorbar et al., 2012). The E4 protein is abundantly expressed in the upper epithelial layers in cells 303 
that support viral genome amplification. E4 is primarily involved in some aspect of virus release or transmission, 304 
as it was shown to induce the disruption of keratin structure, and in promoting proper viral assembly (Doorbar 305 
et al., 1991,Wang et al., 2004).  306 
During the productive HPV life cycle, the genome is maintained as an episome but in almost all high-grade 307 
lesions and tumors, the viral genome is integrated into the host genome. The viral oncoproteins E6 and E7 are 308 
expressed in high-grade intraepithelial neoplasias associated with HPV infection (Bodily and Laimins, 309 
2011,Doorbar et al., 2012). Expression of E6 and E7 is transcriptionally regulated by E2 during the productive 310 
HPV life cycle. In cancer progression, the integration of the viral genome occurs in such a way that disruption of 311 
the E2 open reading frame occurs eliminating the E2-mediated transcriptional control of the early viral region 312 
(Box 2), leading to constitutive expression of E6 and E7 proteins in HPV-associated cancers. The continuous 313 
expression of these two viral oncoproteins contributes to the maintenance of proliferation and malignant 314 
phenotypes of the cancer cells due to their disruptive action on cell cycle checkpoint. Therefore, E6 and E7 are 315 
considered to be potential therapeutic targets for blocking the development of HPV-related cancer. Ideally, 316 
small molecules that target and prevent the interaction of E6 and E7 with cellular proteins may have interesting 317 
antiproliferative potential (Manzo-Merino et al., 2013). Besides E6 and E7, part or all of E1 is transcribed and 318 
translated in neoplasias. The amino-terminal portion of E1 protein or a truncated peptide is essential to bind to 319 
and neutralize over-abundant cyclins that are transcriptionally up-regulated by E7 (Stoler et al., 1992,Lin et al., 320 
2000,Coupe et al., 2012). 321 
 322 
3. Clinical impact of human polyomaviruses  323 
The name polyomavirus is derived from the ability of the first PyV discovered more than 50 years ago to 324 
induce multiple (poly) tumors (oma) in mice. However, most PyVs do not cause tumors in their natural host. 325 
Mouse polyomavirus (MPyVs) and the simian vacuolating agent 40 (SV40) were the first PyVs identified (Atkin et 326 
al., 2009). Two human PyVs were identified in 1971 and were named following the patients’ initials from whom 327 
they were isolated [JC polyomaviruses (JCPyV) was identified in a brain tissue extract from a patient (John 328 
Cunningham) with progressive multifocal leukoencephalopathy (PML) and BK polyomavirus (BKPyV) was isolated 329 
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from the urine of a nephropathic kidney transplant patient of unknown name] (Dalianis and Hirsch, 2013,Hirsch 330 
et al., 2013,Gjoerup and Chang, 2010). Subsequently, more PyVs were identified in mammals and birds. From 331 
2007 on, several new human PyVs have been discovered, including KI (Karolinska Institutet) virus (KIPyV), WU 332 
(Washington University) virus (WUPyV), Merkel cell polyomavirus (MCPyV), HPyV6, HPyV7, HPyV9, 333 
Trichodysplasia spinulosa virus (TSPyV), HPyV10 [Malawi virus (MWPyV and MX polyomavirus (MXPyV) variants], 334 
HPyV12 and Saint Louis Polyomavirus (STLpYV) (Van Ghelue et al., 2012,Pastrana et al., 2013,Ehlers and 335 
Wieland, 2013,Yu et al., 2012,Feltkamp et al., 2013,White et al., 2013).  336 
Serological studies indicate that human PyVs sub-clinically infect the general population with rates ranging 337 
from 35% to 90%, and significant disease is only observed in patients with impaired immune functions (Dalianis 338 
and Hirsch, 2013,Chang and Moore, 2012). Thus, BKPyV has been linked to hemorrhagic cystitis (HC) after 339 
allogenic hematopoietic stem cell transplantation and PyV-associated nephropathy (PyVAN) after kidney 340 
transplantation, while JCPyV is associated with PML in HIV-AIDS, haematological diseases and in autoimmune 341 
diseases treated with certain lymphocyte-specific antibodies (Dalianis and Hirsch, 2013,Bennett et al., 2012,Jiang 342 
et al., 2009).   343 
TSPyV was identified in Trichodysplasia spinulosa, a rare skin disease characterized by virus-induced lytic as 344 
well as proliferative tumor-like features observed in immunosuppressed transplant recipients (Kazem et al., 345 
2012,Wanat et al., 2012,van der Meijden E. et al., 2010,Kazem et al., 2013). MCPyV is associated with a rare skin 346 
cancer, Merkel cell carcinoma (MCC), seen in the elderly and in chronically immunosuppressed individuals 347 
(Spurgeon and Lambert, 2013,Arora et al., 2012). MCPyV is found in at least 80% of MCC and clonal viral 348 
integration and truncating mutations of the Large T antigen (LT-ag) support an etiopathogenic role of MCPyV in 349 
MCC (Feng et al., 2008,Rodig et al., 2012,Shuda et al., 2008). MCPyV might not be exclusively linked to the 350 
development of MCC. The presence of MCPyV DNA has been evaluated in a variety of other cancers since this 351 
virus was linked to MCC (Spurgeon and Lambert, 2013). A potential role of MCPyV in a significant subset of 352 
chronic lymphocytic leukemia (CLL) is claimed based on a study performed on 70 patients (Pantulu et al., 2010). 353 
The authors demonstrated a relative high incidence of MCPyV in highly purified CLL cells in 27.1 % of patients 354 
and the presence of a truncating LT-ag deletion in 8.6% of CLL cases. Thus, MCPyV may represent the molecular 355 
correlate of the long term recognized epidemiologic association of CLL and MCC and vice versa. Additionally, 356 
contradictory reports have been published on the relationship between squamous cell carcinoma (SCC) and 357 
MCPyV. Some groups have found no significant association (Andres et al., 2010,Reisinger et al., 2010) whereas 358 
others found virus DNA in 40% of cutaneous SCC  (Kaibuchi-Noda et al., 2011,Rollison et al., 2012). 359 
In contrast, KIPyV and WUPyV (found in the respiratory tract), HPyV6 and 7 (present in the skin), and HPyV9 360 
(isolated from serum and skin), MWPyV, STLPyV and HPyV12 (found in stool samples) have so far not been 361 
linked to any disease (Ehlers and Wieland, 2013). 362 
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Infections with human PyVs occur early in life leading to a primary viremia followed by a state of 363 
latency/persistence and escape from the immune system. The site and the molecular nature of viral 364 
latency/persistence are not fully understood and differs among human PyVs (White et al., 2013). They can 365 
persist in the host cells in the absence of viral replication, i.e. a state of viral latency, for example JCPyV in the 366 
brain. Alternatively, human PyVs may persist in a state of active but asymptomatic viral replication, as it is the 367 
case for JCPyV and BKPyV in the kidney.  368 
 369 
4. Clinical importance of HPVs 370 
Papillomaviruses have a tropism for squamous epithelia and today, 165 HPV types have been described (Burk 371 
et al., 2013,Bernard et al., 2010), the number is growing as more types are officially classified. Although various 372 
HPV types have a comparable genomic organization, different HPVs infect mucosal or cutaneous epithelia at 373 
distinct body locations. About 48 of the 165 different HPV types are able to infect the anogenital and oral 374 
mucosa, and they can be further classified into low-risk and high-risk types based on their potential to induce 375 
cellular transformation. Low-risk types cause benign epithelial proliferation (warts), while infection with high-376 
risk types may lead to cancer progression. HPV6 and 11 are the most abundant low-risk types, causing more 377 
than 90% of condylomata acuminata (genital warts) (Doorbar et al., 2012). Recurrent respiratory papillomatosis 378 
(RRP) is also caused by low-risk HPV types (mostly HPV6 and 11).  HPV infection leading to RRP occurs mostly 379 
during vaginal delivery but HPV DNA detection in amniotic fluid, foetal membranes, cord blood and placental 380 
trophoblastic cells suggest that HPV infection can also take place in utero, i.e. prenatal transmission (Syrjanen, 381 
2010).  Recurrent respiratory papillomatosis can also arise later in life and, indeed, about half of all RRP cases 382 
first show up in adults. (Derkay and Wiatrak, 2008). 383 
In 2008, H. zur Hausen was awarded the Nobel Prize of Physiology or Medicine because of his research on the 384 
association between high-risk HPV types with premalignant cervical lesions and cancer (zur Hausen H., 2002). 385 
Virtually 100% of cervical cancers contain HPV DNA sequences from a high-risk oncogenic HPV type, HPV16 and 386 
18 being found in about 70% of cases. Besides cervical cancer, HPVs are associated with a number of other 387 
anogenital cancers, including vulvar, vaginal, penile and anal cancers. HPV-associated anogenital cancers are 388 
preceded by a spectrum of intraepithelial abnormalities, ranging in the case of the cervix from low-grade CIN 389 
(cervical intraepithelial neoplasia) 1, moderate CIN2 and high-grade CIN3 (Hellner and Munger, 2011,Cubie, 390 
2013). Genital infections with high-risk HPV types are very common among sexually active individuals and 391 
although the majority of them clear the infection with time, a proportion of women (approximately 15%) cannot 392 
eliminate the virus and persistence with a high-risk HPV type is considered the major risk factor for the 393 
development of malignancies.  394 
High-risk HPVs are also found in a proportion of head and neck squamous cell carcinomas (HNSCC) and it is 395 
recognized that HPV-positive HNSCC present a different biology than that of HPV-negative HNSCC (Miller et al., 396 
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2012,Leemans et al., 2011). Recent studies have shown that the incidence of HPV-negative HNSCC has 397 
decreased as a consequence of public efforts encouraging smoking cessation and reduced consumption of 398 
alcohol, in contrast to HPV-positive HNSCC whose incidence is increasing (most likely due to changes in sexual 399 
behaviour) (Olthof et al., 2012,Rietbergen et al., 2013). 400 
 401 
5. PME derivatives 402 
5.1 In vitro and in vivo antiproliferative activities  403 
PMEG was studied for effectiveness against cotton tail rabbit papillomavirus (CRPV) infection of rabbits and 404 
HPV11 infection of human foreskin xenografts in athymic mice (Kreider et al., 1990). PMEG strongly suppressed 405 
the growth rates of Shope papillomas and inhibited HPV11 infections of human skin. Although drug toxicity 406 
paralleled the therapeutic effects in rabbits, there was much less toxicity in athymic mice. 407 
Three phosphonomethoxyalkyl purine analogues, i.e. HPMPA {(S)-9-[(3-hydroxy-2-408 
phosphonylmethoxy)propyl]adenine}, PMEA, and PMEG proved modestly active against intraperitoneal injected 409 
P388 murine leukemia cells in mice, PMEG being the most active and most potent of the three compounds (Rose 410 
et al., 1990). In this study, PMEG was also evaluated against subcutaneously implanted B16 melanoma in mice, 411 
affording increased life span and delay in primary tumor growth.  412 
When the PME analogues PMEA, PMEDAP and PMEG were evaluated for their in vitro antitumor efficacy 413 
against human leukemia cells (Franek et al., 1999), they caused reversible slowdown of growth at low 414 
concentrations due to continuous repairing of damaged DNA, while high concentrations induced apoptosis and a 415 
reduction of the proportion of cells in the G1 phase of the cell cycle. The antitumor properties of these 416 
analogues increased in the order PMEA<PMEDAP<PMEG.  417 
PMEG, PMEA, and PMEDAP were also investigated in a model of spontaneous T-cell lymphoma in inbred 418 
SD/cub rats (Otova et al., 1999). Treatment with 16 daily doses of PMEDAP at 5 mg/kg applied to the vicinity of 419 
the growing lymphoma resulted in significant therapeutic effects while daily PMEA or PMEG administration 420 
(although at lower doses than those of PMEDAP) did not affect survival of lymphoma-bearing mice. PMEDAP 421 
was shown to induce apoptosis in this in vivo model of hematological malignancies.  422 
Because the utility of PMEG as an anticancer agent is limited by poor cellular permeability and toxicity 423 
(especially for the kidney and gastrointestinal tract), prodrugs such as N6-cyclopropyl-PMEDAP (cPr-PMEDAP),  424 
GS-9191 and GS-9219 (Figure 2) have been designed to increase permeability and accumulation of PMEGpp 425 
intracellularly (Kreider et al., 1990,Compton et al., 1999,Vail et al., 2009,Wolfgang et al., 2009). cPr-PMEDAP is 426 
converted to PMEG and can be considered as an intracellular prodrug of PMEG, limiting plasma exposure to the 427 
toxic agent PMEG. cPr-PMEDAP showed higher antitumor efficacy and selectivity in choriocarcinoma-bearing 428 
rats compared to PMEDAP or PMEG (Naesens et al., 1999) and was reported to have 8- to 20-fold more 429 
14 
 
pronounced cystostatic activity than PMEDAP and equivalent activity as PMEG against a variety of tumor cell 430 
lines (Hatse et al., 1999a). 431 
GS-9191, a double prodrug of PMEG, was specifically designed as a topical agent to permeate the skin and to 432 
be metabolized to the active form in the epithelial layer. The conversion of GS-9191 to cPr-PMEDAP was shown 433 
to occur in lysosomes via carboxypeptidase cathepsin A-mediated ester cleavage, being cPr-PMEDAP 434 
subsequently translocated to the cytosol where it undergoes deamination and phosphorylation, yielding the 435 
active metabolite PMEGpp (Birkus et al., 2011). Recently, it was demonstrated that the adenosine deaminase-436 
like (ADAL) protein plays a key role in the deamination of cPr-PMEDAP to produce PMEG, as mutations in this 437 
enzyme were shown to confer resistance to cPr-PMEDAP and its prodrugs but not to PMEG (Frey et al., 2013). 438 
On the other hand, resistance to both PMEG and cPr-PMEDAP was associated with a decreased capacity of the 439 
resistant cells to metabolically activate (phosphorylate) PMEG, resulting from amino acid substitutions in the 440 
guanylate kinase (involved in the conversion of PMEG to PMEGp) (Mertlikova-Kaiserova et al., 2011). 441 
GS-9191 administered topically decreased the size of papillomas in a dose-dependent manner in an animal 442 
model of CRPV, affording the highest dose (0.1%) evident cures at the end of 5 weeks (Wolfgang et al., 2009). 443 
Based on these encouraging findings, topical GS-9191 was evaluated in a Phase II clinical trial (ClinicalTrials.gov 444 
Identifier: NCT00499967) for the treatment of genital warts in 2009 by Graceway Pharmaceuticals but the 445 
results of this trial have not been published (http://clinicaltrials.gov). 446 
GS-9219, a phosphonoamidate prodrug of PMEG was designed as a cytotoxic agent that preferentially targets 447 
lymphoid cells in vivo, releasing PMEG in a two-steps process via enzymatic hydrolysis and deamination (Reiser 448 
et al., 2008). GS-9219 displayed considerable antiproliferative activity against activated lymphocytes and 449 
hematopoietic tumor cell lines while resting lymphocytes and solid tumor cell lines were less sensitive to the 450 
compound. GS-9219 showed substantial in vivo efficacy in five dogs with advanced-stage non-Hodgkin's 451 
lymphoma (NHL) after a single intravenous administration, with either no or low-grade adverse events (Reiser et 452 
al., 2008). In a Phase I/II trial conducted in pet dogs (n = 38) with naturally occurring NHL using different dose 453 
schedules of GS-9219, the compound was generally well tolerated and showed significant activity (Vail et al., 454 
2009). Antitumor responses were observed in 79% of dogs and occurred in previously untreated dogs and dogs 455 
with chemotherapy-refractory NHL. Recently, GS-9219 (currently referred as VDC-1101) was evaluated against 456 
three human multiple myeloma (MM) cell lines, showing a dose-dependent antiproliferative activity (Thamm et 457 
al., 2014). In a Phase II clinical trial in dogs with spontaneous MM, major antitumor responses were observed in 458 
9 of 11 evaluable dogs for a median of 172 days (Thamm et al., 2014). 459 
Hostetler’s group has synthesized alkoxyalkyl esters of PMEG and compared their antiproliferative activities 460 
with unmodified PMEG in primary human fibroblasts and CaSki, Me-180 and HeLa human cervical cancer cell 461 
lines in vitro (Valiaeva et al., 2010). Octadecyloxyethyl (ODE)-PMEG had excellent antiproliferative activity in 462 
vitro against the different human cervical carcinoma cell lines. In a Me-180 xenograft model in athymic nude 463 
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mice, intratumoral injection of 25 µg of ODE-PMEG or 100 µg of ODE-CDV daily for 21 days resulted in near-464 
complete disappearance of measurable tumors, suggesting that ODE-PMEG may be suitable for local or topical 465 
treatment of cervical dysplasia. 466 
5.2 Mechanism of antiproliferative effects of PME derivatives  467 
As mentioned above, to exert their antiviral or antiproliferative activity, the PME derivatives need to be 468 
converted by cellular enzymes to their diphosphate forms. Studies performed with purified viral and cellular 469 
enzymes showed that the diphosphate metabolites effectively compete with the corresponding 470 
deoxynucleoside triphosphate (dGTP or dATP) for incorporation into DNA. As the diphosphate forms of PME 471 
derivatives are recognized as substrates by cellular DNA polymerases, they are able to inhibit cellular DNA 472 
synthesis by a direct inhibition of replicative cellular DNA polymerases. Indeed, a close correlation between 473 
cytostatic activities of PME derivatives and the inhibitory effects of their active metabolites on cellular DNA 474 
polymerases α, δ, and ε was established, emerging PMEG as the most potent chain terminating inhibitor of 475 
cellular DNA polymerases (Kramata et al., 1996,Kramata et al., 1998). Thus, the primary mechanism of action of 476 
PMEG in replicating cells is incorporation of its active metabolite PMEGpp into DNA and subsequent chain 477 
termination due to the lack of a 3’-hydroxy moiety.  478 
Of note, PMEGpp was found to be more efficiently incorporated into DNA by DNA polymerases α and δ than 479 
by DNA polymerases β, γ, and ε (Kramata et al., 1996,Kramata et al., 1998). The interaction of PMEGpp with 480 
purified rat pol α, β, and δ, bovine pol δ and human pol ε were investigated by using oligonucleotide template-481 
primers and by examining the inhibitory effects of PMEGpp and the ability of these enzymes to incorporate the 482 
analogue into DNA as well as to excise it from 3′-ends. DNA polymerases α (associated with primase activity) and 483 
δ are required for DNA synthesis of, respectively, the lagging strand and the leading strand of chromosomal DNA 484 
while DNA polymerase ε is required as a second DNA polymerase on the lagging DNA strand. In contrast to DNA 485 
polymerase α, both DNA polymerases δ and ε have intrinsic 3’-5’-exonuclease activity associated with a 486 
proofreading function and are necessary for the repair of DNA damage. While both enzymes can recognize 487 
PMEGpp as a substrate and can incorporate PMEG into DNA, DNA polymerase ε but not δ was shown to be able 488 
to repair the incorporated analogue (Kramata et al., 1998).  489 
Wolfgang and collaborators investigated the mechanism of inhibition of PMEG and its prodrug GS-9191 490 
against HPV (Wolfgang et al., 2009). Inhibition of DNA polymerases by PMEGpp was proposed as the prevailing 491 
mechanism of action, and this activity alone may explain their antiproliferative activity against cervical 492 
carcinoma HPV positive cells. Treatment of cells with these drugs resulted in inhibition of DNA synthesis and S-493 
phase arrest leading to apoptosis induction. Thus, PMEG and GS-9191 preferentially affect rapidly dividing HPV-494 
transformed cells (compared to normal keratinocytes, the majority of which are quiescent) because the 495 
inhibition of chromosomal DNA replication affects only cells in the S-phase of the cell cycle. In conclusion, due to 496 
the lack of an HPV viral polymerase, the active metabolite PMEGpp exerts its effect by inhibiting host cell 497 
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polymerases, and in vivo, partial selectivity for virally infected cells is likely derived based on the increased 498 
proliferation of infected cells and due to the fact that the compounds are locally administered.  499 
Kramata and collaborators demonstrated that differences in inhibition of cellular DNA synthesis by PMEG, 500 
PMEDAP, and PMEA may be explained not only by different affinities of DNA polymerases (primarily DNA 501 
polymerase δ) for the nucleotide analogues but also by different intracellular ratios of the diphosphate 502 
analogues to their corresponding deoxynucleoside triphosphates (Kramata et al., 1996). Treatment of the 503 
human T lymphoblast cell line CEM with PMEG, PMEDAP or PMEA resulted in increased deoxynucleotide 504 
triphosphate (dNTP) pools, with PMEG producing the greatest increase. Although no significant differences in 505 
cellular uptake were found for these ANPs, CEM cells were found to accumulate higher levels of PMEGpp than 506 
PMEDAPpp or PMEApp, pointing also to differences in the efficiency of phosphorylation among these nucleotide 507 
analogues (Pisarev et al., 1997). It is interesting to note that more PMEGpp than PMEApp are produced 508 
considering that there is much more adenylate kinase than guanylate kinase in the cells resulting in more 509 
ADP/ATP than GDP/GTP.  The investigations carried out by Pisarev and colleagues also highlighted that the 510 
factors contributing to the enhanced antileukemic activity of PMEG derives both from its increased anabolic 511 
phosphorylation and the increased potency of PMEGpp to target the cellular DNA polymerases compared to 512 
other PME analogues. 513 
PMEA proved to be a strong inducer of differentiation of the erythroleukemia K562 cell line, as evidenced by 514 
hemoglobin production, increased expression of glycophorin A on the cell membrane, and induction of 515 
acetylcholinesterase activity (Hatse et al., 1999b). After exposure to PMEA, K562 cell cultures displayed a marked 516 
retardation of S-phase progression, leading to a severe perturbation of the normal cell cycle distribution pattern 517 
with marked accumulation of cyclin A and, most strikingly, cyclins E and B1. A similar effect on cell cycle 518 
deregulation was also observed in PMEA-exposed human myeloid THP-1 cells but, in contrast to the strong 519 
differentiation-inducing activity of PMEA in K562 cells, the drug completely failed to induce monocytic 520 
maturation of THP-1 cells. On the contrary, THP-1 cells underwent apoptotic cell death in the presence of PMEA. 521 
These data suggested that, depending on the nature of the tumor cell line, PMEA can trigger a process of either 522 
differentiation or apoptosis by affecting cell cycle processes through inhibition of DNA replication during the S 523 
phase. 524 
Among several diphosphates of ANPs tested in a telomeric repeat amplification protocol (TRAP) for their 525 
ability to inhibit the extension of telomeres by human telomerase, the diphosphates of PMEG and PMEDAP 526 
emerged as the most potent drugs (Hajek et al., 2005). In this study, the ability of well-known inhibitors of the 527 
HIV reverse transcriptase to interfere with telomerase activity was investigated as the human telomerase active 528 
site (i.e. hTERT) was shown to function as a reverse transcriptase. However, the most potent chain-terminating 529 
inhibitors of retroviral reverse transcriptase (such as PMPApp and PMPDAPpp) did not inhibit human telomerase 530 
activity. In fact, PMEGpp (IC50 12.7 ± 0.5 mmol at 125 mmol deoxynucleoside triphosphates (dNTPs) emerged as 531 
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the most potent inhibitor of human telomerase in vitro, consistent with the antitumor activities of PMEG. The 532 
PMEG-MP and PMEG itself did not show any effect on telomerase activity. The effects of PMEG on telomerase 533 
appear to be marginal compared to the inhibition of cellular DNA polymerases by PMEG-DP [IC50 = 2.50 ± 0.97 534 
µM (DNA polymerase α), 1.60 ± 0.53 (DNA polymerase β) and 59.4 ± 17.6 (DNA polymerase γ) (Wolfgang et al., 535 
2009). 536 
In a follow-up study, the authors found that PMEG and PMEDAP were able to differently modulate telomere 537 
length in T-lymphoblastic leukemia cell lines (Hajek et al., 2010). The most striking difference concerned the 538 
CCRF-CEM and MOLT-4 cells. While in CCRF-CEM cells delayed and progressive telomere shortening was 539 
observed, MOLT-4 cells responded to the treatment by a rapid telomere elongation that could be observed as 540 
early as after 3 days of incubation and remained elevated throughout the treatment. This cell specific effect on 541 
telomere shortening was not due to direct telomerase inhibition or impairment of hTERT expression. Hajec and 542 
collaborators (Hajek et al., 2010) speculated about the mechanism of the observed telomere elongation in 543 
MOLT-4 cells. Considering that both PMEG and PMEDAP can activate and up-regulate poly (ADP-544 
ribose)polymerase (PARP), a similar effect can be possibly anticipated on tankyrase, which is a telomeric protein 545 
possessing PARP activity. Tankyrase inhibits binding of TRF1 to telomeric DNA in vitro, where under normal 546 
conditions TRF1 prevents the access of telomerase to telomeric complex. Therefore, overexpression and/or 547 
activation of tankyrase in telomerase positive cells may induce telomere elongation without a direct effect on 548 
telomerase activity. Another possible explanation of the increase in the mean telomere length can be activation 549 
of a different telomere maintenance mechanism, termed “alternative lengthening of telomeres” (ALT), a 550 
recombination mediated process that enables survival of telomerase-negative cancer cells. It was also suggested 551 
that the factors determining the PMEG- and PMEDAP-induced telomere shortening might depend on p53 552 
functional status (CCRF-CEM – mutated, MOLT-4 – wild-type since telomere length is connected with p53 553 
expression and functional status and cells with mutated p53 may be more susceptible to telomere shortening 554 
induced by external stimuli (chemotherapy, irradiation, etc.).  Besides, oxidative degradation of telomeres by 555 
reactive oxygen species leaking from the damaged mitochondria following treatment with PMEG and PMEDAP 556 
may affect telomere length as cells treated with these drugs  were found to contain elevated levels of reactive 557 
oxygen species and telomeres have been shown to be highly susceptible to oxidative stress. 558 
Otova and co-workers suggested that DNA-damage induced by ANPs should affect signalling pathways 559 
associated with cell proliferation, apoptosis and angiogenesis (Otova et al., 2009). They demonstrated that the 560 
antitumor efficacy of PMEG and PMEDAP in spontaneous lymphomas in rats was not only caused by inhibition of 561 
DNA synthesis but also by an effect on angiogenesis, a process stimulated by the secretion of various signalling 562 
molecules to promote neovascular formation. PMEG was found to down-regulate selected proangiogenic genes 563 
much more efficiently than PMEDAP (Otova et al., 2009). 564 
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In addition, the involvement of mitogen activated protein kinases (MAPKs) in the cytotoxicity of PME 565 
derivatives has also been reported in leukemic cell lines (Mertlikova-Kaiserova et al., 2012). MAPKs comprise a 566 
family of serine/threonine kinases that convert extracellular signals, such as stress stimuli and cytokines, into a 567 
variety of cellular processes including cell proliferation, survival, death, and differentiation. The best 568 
characterized groups of MAPKs in mammals include the extracellular signal-related kinases (ERK), c-Jun N-569 
terminal kinase (JNK) and p38. The ERK and p38 pathways were found to be activated by PMEG and PMEDAP in 570 
leukemic cells and pretreatment with a p38 inhibitor diminished PMEG- and PMEDAP-induced apoptosis 571 
whereas inhibition of ERK, JNK or AKT (also known as protein kinase B) pathways did not (Mertlikova-Kaiserova 572 
et al., 2012). 573 
 574 
6. Cidofovir activity against viruses not encoding for their own DNA polymerases 575 
CDV can be given intravenously, intralesional or topically. Systemic administration of the drug requires co-576 
administration of oral probenecid and intravenous hydration in order to prevent nephrotoxicity which is the 577 
dose-limiting clinical adverse effect of CDV. The drug is accumulated in the kidney where it reaches significantly 578 
higher concentration levels compared with other organs and tissues (Cundy et al., 1996,Cundy, 1999). The 579 
uptake of CDV across the basolateral tubular membrane is more efficient than the subsequent secretion into 580 
tubular lumen resulting in drug accumulation in renal tubules. CDV was shown to be a substrate for human and 581 
rat renal organic transport 1 (OAT1) and intravenous hydration and administration of oral probenecid [an 582 
inhibitor of OAT1 that interferes with the transporter-mediated tubular uptake of cidofovir] are used in order to 583 
prevent CDV-induced nephrotoxicity (Cihlar et al., 1999,Cihlar et al., 2001).   584 
CDV is given mostly systemic for the management of PyV-associated diseases, although Intravesical CDV-585 
instillation therapy for polyomavirus-associated hemorrhagic cystitis (Koskenvuo et al., 2013,Eisen et al., 586 
2009,Mackey, 2012) and topical CDV for treatment of trichodysplasia spinulosa virus (TSPyV) (van der Meijden E. 587 
et al., 2010,Wanat et al., 2012) have been reported.  588 
 CDV has been mostly used intralesional or topically for the management of HPV-related diseases, being the 589 
therapy usually well-tolerated with minimal, if any, side effects, pointing to the selectivity of CDV for the 590 
affected tissue. In case of appearance of local side effects (presented as ulcerations at the site of the affected 591 
mucosa but not in the surrounding normal tissue), these are self-limiting and do not need cessation of treatment 592 
(Stier et al., 2013,Tjon Pian Gi et al., 2013).  593 
Although polyoma- and papillomaviruses lack their own polymerases, off-label use of CDV, mostly in 594 
immunocompromised individuals, has proven effective in the management of diseases caused by HPV. The 595 
compound has also been used off-label for therapy of human PyV-associated illnesses with more controversial 596 
results. A puzzling situation has been why cidofovir inhibits papilloma- and polyomaviruses even though the 597 
effects of CDVpp on cellular DNA polymerization are weak compared to PMEG [inhibition constant (Ki) of CDVpp 598 
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for cellular DNA polymerase α of 51 µM versus 0.55 µM for PMEGpp] (Wolfgang et al., 2009,Kramata et al., 599 
1996,Kramata et al., 1998). Another important difference between PME derivatives and CDV is the fact that 600 
CDVpp can still be incorporated during DNA elongation as CDV has a 3’-OH moiety. 601 
6.1 In vitro, in vivo and clinical evidences for the anti-polyomavirus activity of CDV 602 
CDV proved active against murine and primate non-human PyVs (i.e. SV40) (Andrei et al., 1997,Lebeau et al., 603 
2007) as well as against human BKPyV and JCPyV (Topalis et al., 2011,Farasati et al., 2005,Gosert et al., 604 
2011,Rinaldo et al., 2010) replication in vitro. Despite CDV shows modest in vitro activity against BKPyV, CDV is 605 
the drug most frequently used clinically to block BKPyV replication. Although the data are based solely on case 606 
reports, CDV does appear to be effective, albeit inconsistently, for the treatment of BKPyV and JCPyV infections 607 
(Kwon et al., 2013,De Luca et al., 2008,Ripellino et al., 2011,Savona et al., 2007). CDV proved also active in cases 608 
associated with productive infection of TSPyV and MCPyV in immunocompromised patients when the drug was 609 
administered topically (van der Meijden E. et al., 2010,van Boheemen et al., 2014,Wanat et al., 2012) or 610 
intravenously (Maximova et al., 2013) . CDV has been used mostly systemic for the management of BKPyV and 611 
JCPyV related diseases, although intravesical instillation of CDV has been used to manage BKPyV-associated 612 
hemorrhagic cystitis in hematopoietic stem cell transplant recipients (Koskenvuo et al., 2013,Cesaro et al., 613 
2013,Ganguly et al., 2010).  614 
For the management of BKPyV infections, a low dose intravenous CDV regimen of 0.25-1.0 mg/kg weekly is 615 
used empirically. The use of adjuvant low-dose CDV therapy was shown to result in prolonged graft survival and 616 
stabilized graft function in renal transplant recipients suffering from BKPyV interstitial nephritis (Kuypers et al., 617 
2005). A recent study has demonstrated that CDV clearance and the mean estimated glomerular filtration rate in 618 
renal transplant recipients with persistent BKPyV viremia without nephropathy were linearly related irrespective 619 
of probenecid administration (Momper et al., 2013). Based on this relationship, the systemic exposure to CDV in 620 
individual patients can be predicted and may be used to evaluate exposure-response relationships to optimize 621 
CDV dosing regimen for BKPyV infection. 622 
 One may question why inconsistent results have been reported for CDV in the therapy of human PyV-623 
associated diseases. It can be hypothesized that the pathology resulting from the relative contributions of viral 624 
replication and host response in human PyV-associated diseases may explain, at least in part, why the efficacy of 625 
CDV may vary among different patients. The diverse human PyV pathologies are the consequence of diverse 626 
viral and immunological processes that drive the disease, as reviewed by (Dalianis and Hirsch, 2013). For some 627 
human PyV pathologies such as PyVAN, HC, and PML, a reduction in viral load may be a good marker of efficacy 628 
of an antiviral drug because these pathologies are associated with high levels of viral replication. However, in 629 
cases of autoimmune or oncogenic pathology that is independent of viral replication, other markers for drug 630 
efficacy need to be developed.  631 
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The usefulness of CDV for the treatment of PML in HIV-positive patients is rather controversial. There are 632 
studies supporting a therapeutic efficacy of CDV (De Luca et al., 2000,De Luca et al., 1999) but its activity was 633 
not proven in a multicohort analysis (De Luca et al., 2008).  Similarly, in HIV-negative patients some studies 634 
report efficacy (Naess et al., 2010,Viallard et al., 2007,Viallard et al., 2005) and others lack of activity (Osorio et 635 
al., 2002). If one considers that restoring the immune response in the host is one of the crucial steps in PML 636 
therapy in HIV-negative individuals and highly active antiretroviral therapy is the first treatment option for PML 637 
in HIV-positive patients, the immune status of the patient, the time of addition and dose of CDV administered 638 
may indeed have an impact on the response to treatment. 639 
Of particular relevance in the treatment of PML is the question of the penetration of CDV across the blood-640 
brain barrier because according to the product labelling there is no penetration of the drug into the CNS 641 
following intravenous administration.  642 
A point that needs to be mentioned is the challenge of diagnosing PML in patients with sarcoidosis because 643 
neurosarcoidosis presents a similar pathology to that seen in PML. While neurosarcoidosis is usually treated with 644 
steroid therapy, this treatment results in enhancement of JCPyV replication in PML. Therefore, a misdiagnosis of 645 
PML may explain the lack of activity of CDV in patients previously receiving steroid therapy (Volker et al., 646 
2007,Granot et al., 2009). Recent reports demonstrated the efficacy of CDV alone (De Raedt et al., 2008) or in 647 
combination with the anti-depressant mirtazapine (a blocker of receptors used by JCPyV to infect human glial 648 
cells) (Owczarczyk et al., 2007,Park et al., 2011) for the therapy of PML in patients with sarcoidosis that did not 649 
receive previous steroid treatment. Furthermore, combination of CDV and mirtazapine found to be helpful in the 650 
treatment of PML in HIV-negative patients (Ripellino et al., 2011). 651 
Most predisposing risk factors for BKPyV reactivation and development of PyVAN are directly or indirectly 652 
associated with the function and activity of the immune response. Issues to be considered include: age of the 653 
patient and of the donor, viral co-infections, placement of urethral stents, the degree of HLA mismatch, episodes 654 
of acute rejection, BKPyV-specific antibody status, male sex, white ethnicity, being immunosuppressive therapy 655 
and its intensity the most important risk factor (Babel et al., 2011). As these factors might trigger or promote 656 
viral replication and increase susceptibility to PyVAN, they may affect the efficacy of adjuvant therapies, such as 657 
CDV. A comparison of the available data from case series and retrospective studies is further complicated by 658 
differences in the type of immunosuppressive therapy, patient’s characteristics, CDV doses (varying from 0.25 659 
mg/kg to 1 mg/kg), duration of treatment (3-10 weekly cycles) and use of probenecid (Kuypers, 2012). 660 
A reduction of immunosuppression (which facilitates re-establishment of BKPyV-specific immunity) is used to 661 
prevent graft failure in many patients (Babel et al., 2011). However, this approach does not work in all 662 
individuals, raising questions about the reasons why patients respond differently following treatment with 663 
comparable protocols. Based on the pathogenesis of PyVAN, a reduction of immunosuppression can lead to a 664 
beneficial outcome only at an early stage of BKPyV infection while reduction of immunosuppressive therapy can 665 
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be damaging in patients with persistent, uncontrolled BKPyV replication and may not be considered as a 666 
therapeutic option. Thus, a reduction of immunosuppression to improve antiviral immunity appears to be more 667 
harmful than beneficial in patients with long-lasting BKPyV infection and this may also impact the effects of 668 
adjuvant therapies such as CDV.  669 
Although supportive care has been the standard of treatment for HC during many years, several clinical 670 
studies have demonstrated successful use of CDV for BKPyV-HC after hematopoietic stem cell transplantation 671 
not only in adults but also in children (Savona et al., 2007,Cesaro et al., 2013,Gaziev et al., 2010).  Important 672 
factors in the pathogenesis of HC involve severe immune suppression together with urothelial damage due to 673 
conditioning and radiation (which creates a favourable environment for viral replication and leads to an 674 
augmentation in immunological signals and antigen presentation) and the attack of virus-infected urothelial cells 675 
by donor T cells. Additional risk factors for HC include donor origin, NCCR (non-coding control region) viral 676 
mutants, treatment with anti-thymocyte globulins and type of conditioning. All these factors may influence the 677 
response to adjuvant therapies.  678 
6.2   Polyomavirus replicative cycle: potential targets for CDV 679 
It has been shown that CDV does not affect early steps of PyV replication such as receptor binding and entry 680 
(Bernhoff et al., 2008). Neither initial transcription nor expression of the LT-ag was impaired by CDV. However, 681 
the drug reduced intracellular BKPyV DNA replication by >90% while at equivalent concentrations a reduction of 682 
cellular DNA replication and metabolic activity of 7% and 11%, respectively, in uninfected human renal tubular 683 
cells was found. Furthermore, BKPyV infection increased cellular DNA replication to 142% and metabolic activity 684 
to 116%, respectively, which were reduced by CDV to levels of uninfected untreated cells.  685 
Our laboratory selected SV40 mutants resistant to CDV, following growth of the virus in increasing drug-686 
concentration in the Monkey African green kidney epithelial cell line BSC-1. This system was used because the 687 
entire lytic replicative cycle of SV40 is accomplished. CDV-resistant viruses bear mutations in the ORI and 688 
helicase domains of the LT-ag, indicating that the helicase activity required for viral DNA unwinding during 689 
replication may be affected by CDV (our unpublished data). Further research is required to prove that the 690 
helicase/ATPase activity of the LT-ag is affected by CDV and/or its metabolites.  691 
Interference with the helicase/ATPase activity of the LT-ag may explain the activity of CDV during PyV 692 
productive infection but not against PyV-induced tumors. Liekens and collaborators reported the activity of CDV 693 
against cerebral hemangiomas induced following intraperitoneal inoculation of newborn rats with mouse PyV 694 
(Liekens et al., 1998). The drug was able to completely suppress hemangioma development even when applied 3 695 
days following viral inoculation and resulted in 40% survival and delay in tumor-associated mortality when 696 
treatment started at the time cerebral hemangiomas were macroscopically visible (i.e. 9 days post-viral 697 
infection). Infectious virus or viral DNA were not detected in the brain of the infected animals at any time post-698 
infection, indicating that there was not viral replication in mouse PyV-infected rats and that an antitumor effect 699 
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of CDV should be responsible for the activity of the drug in this model. A similar mode of action was postulated 700 
to explain the efficacy of CDV on the growth of hemangiosarcomas in mice originating from PyV-transformed 701 
(PV/2b/35) cells which do not produce infectious virus but express the viral T antigen (Liekens et al., 2001). CDV 702 
was also found to induce apoptosis in the hemangiosarcomas. 703 
CDV anti-proliferative effects against PyVs can be explained by the cells infected by PyV being more 704 
sensitive to the drug because of the effects of the LT-ag on G1/S cell checkpoint deregulation. This is sustained 705 
by the higher antiproliferative effects of CDV against LT-ag transformed cells compared to the corresponding 706 
non-transformed cells (Andrei et al., 1998a).  707 
 708 
6.3 In vitro, in vivo and clinical evidences for the anti-papillomavirus activity of CDV 709 
The in vitro antiproliferative activities of CDV were first reported in 1998 (Andrei et al., 1998a) and later 710 
confirmed in several studies (Johnson and Gangemi, 1999,Johnson and Gangemi, 2003,Abdulkarim and Bourhis, 711 
2001,Abdulkarim et al., 2002). CDV was shown not only to inhibit the growth of cervical carcinoma xenografts in 712 
athymic nude mice (Andrei et al., 1998b,Yang et al., 2010), but also to improve the pathology associated with 713 
tumor growth (De Schutter et al., 2013a). Intratumoral administration of CDV resulted in a beneficial effect on 714 
body weight gain, a reduction in splenomegaly, a partial restoration of tryptophan catabolism, and diminished 715 
the inflammatory state induced by the xenografts. The beneficial effect of CDV on the host inflammatory 716 
response was evidenced by a reduction in the number of immune cells in the spleen, histopathology of the 717 
spleen and levels of host pro-cachectic cytokines. Also, a decrease in tumor (human)-derived cytokines was 718 
measured following CDV administration. Furthermore, the positive effects of intratumoral CDV (including 719 
increased body weight gain and decreased inflammatory response) correlated with a reduction in tumor size (De 720 
Schutter et al., 2013a). 721 
CDV is the only ANP successfully used as an antiproliferative agent in humans. Several reports have 722 
highlighted the efficacy of CDV against HPV-associated malignancies, including hypopharyngeal and esophageal 723 
(Van Cutsem et al., 1995), gingival and oral neoplasias (Collette and Zechel, 2011) as well as several anogenital 724 
neoplasias such as cervical (Snoeck et al., 2000,Van Pachterbeke et al., 2009), vulvar (Koonsaeng et al., 725 
2001,Tristram and Fiander, 2005,Stier et al., 2013), and perianal intraepithelial neoplasias (Snoeck et al., 1995). 726 
It should be noted that in the neoplasias successfully treated with CDV, no viral productive infection is detected 727 
and only a limited number of viral genes are expressed. 728 
Over the last years, CDV has increasingly been used as therapy for severe recurrent anogenital warts 729 
associated with the low-risk HPV6 and HPV11 types (Coremans and Snoeck, 2009,Gormley and Kovarik, 730 
2012,Calisto and Arcangeli, 2003). The efficacy of CDV for this indication has been documented in several case 731 
reports as well as in two clinical trials [one in immunocompetent individuals (Snoeck et al., 2001) and the other 732 
one in HIV-infected patients (Matteelli et al., 2001)]. CDV has also been employed to manage recalcitrant cases 733 
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of verruca vulgaris, mosaic verruca plana, and different skin lesions caused by HPV (Stragier et al., 2002,Bonatti 734 
et al., 2007,Kralund et al., 2011,Field et al., 2009).  735 
Importantly, following the first report on the use of CDV for the treatment of severe RRP in 1998 (Snoeck et 736 
al., 1998), the application of the drug as adjuvant  therapy for severe cases of RRR has been documented by 737 
several investigators (Derkay et al., 2013,Mikolajczak et al., 2012,Ksiazek et al., 2011,Derkay and Wiatrak, 2008). 738 
Although there were some anecdotal reports documenting serious adverse reactions in RRP in off-label use of 739 
CDV (Tjon Pian Gi et al., 2012), a multicentre retrospective chart review involving 16 hospitals from 11 countries 740 
worldwide with 635 RRP patients (of whom 275 were treated with CDV) was performed. In this study, no clinical 741 
evidence was found for more long-term nephrotoxicity, neutropenia or laryngeal malignancies after intralesional 742 
administration of CDV (Tjon Pian Gi et al., 2013). In another recent study, it was concluded that CDV remains the 743 
leading option for adjuvant treatment of patients with RRP of all ages whose disease is difficult to manage with 744 
surgery alone. CDV represents an option to reduce the risks of frequent surgical debulking and airway 745 
obstruction in children and adults with recurrent or severe disease (Derkay et al., 2013).   CDV is nowadays 746 
recognized as an adjuvant therapy for the management of this disease (Tjon Pian Gi et al., 2013,Graupp et al., 747 
2013). A type specific real-time PCR to measure HPV6 and HPV11 DNA loads in patients with recurrent 748 
respiratory papillomatosis treated with CDV, indicated that the drug significantly reduced viral load following 749 
intralesional application (Mikolajczak et al., 2012). Although CDV has been reported to be ineffective in the 750 
treatment of epidermodysplasia verruciformis (a rare inherited disease characterized by widespread HPV 751 
infection of the skin) (Preiser et al., 2000), a more recent study documented its efficacy against 752 
epidermodysplasia verruciformis caused by novel HPV types (Darwich et al., 2011). 753 
 754 
6.4 Why is CDV selective against HPV-induced hyperproliferation? 755 
The anti-proliferative effects of CDV against HPV-induced transformation have intensively been studied the 756 
last years. The first studies showing the cytostatic activity of the drug against cervical carcinoma cells date from 757 
1998 (Andrei et al., 1998a), where CDV and related ANPs displayed time-dependent anti-proliferative effects, in 758 
contrast to what is normally seen with chemotherapeutic drugs. HPV- and PyV-transformed cells appeared to be 759 
more sensitive to the effects of CDV due to the fact that the viral oncoproteins induce cellular proliferation 760 
making the cells more sensitive to the anti-proliferative drug effects. Thus, the activity of CDV against HPV- and 761 
PyV-transformed cells may be explained, at least in part, by an inhibitory effect of the compound on rapidly 762 
dividing cells, and the presence of the HPV or PyV genome might enhance the sensitivity of the cells to CDV. 763 
When various cell lines not containing HPV (i.e. human melanomas, lung carcinomas, colon carcinomas, breast 764 
carcinomas) were tested, CDV also showed an anti-proliferative effect (Andrei et al., 1998a). 765 
CDV was demonstrated to induce apoptosis in cervical carcinoma cell lines and to arrest the cells in the S-766 
phase of the cell cycle with increased levels of the tumor suppressor proteins p53 and pRb and of the cyclin-767 
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dependent kinase inhibitor p21/WAF-1. Thus, CDV was able to restore the function of p53 and pRb, which are 768 
neutralized by the oncoproteins E6 and E7, respectively, in HPV-transformed cells (Andrei et al., 2000). Induction 769 
of apoptosis by CDV was confirmed later in several tumor models, including human cancer xenografts in athymic 770 
nude mice (Yang et al., 2010,Abdulkarim et al., 2002).   771 
CDV proved to reduce E6 and E7 expression in the HPV-18 positive cervical carcinoma ME-180 cells and in the 772 
HEP-2 cells (originally believed to be derived from a head and neck squamous cell carcinoma but later turned out 773 
to be HeLa cells) at the transcriptional level with subsequent reactivation of p53 and pRb (Abdulkarim et al., 774 
2002). In a model of stromal-derived factor 1 (SDF-1α)-stimulated invasiveness of HPV-positive cells, CDV had 775 
anti-metastatic action which was mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signalling (Amine et al., 776 
2009).  777 
Donne and co-workers tested the effects of CDV on the non-HPV cervical carcinoma cell line C33A compared 778 
to two derived cell lines, i.e. the C33AT6E6 cells (stable transfected with the low risk HPV6 E6) and the 779 
C33AT16E6 cells (stable transfected with the high-risk HPV16 E6). The authors found that CDV treatment had a 780 
marked growth-inhibitory effect on high-risk E6 expressing C33AT16E6 cells, supporting the use of CDV for 781 
treatment of high-risk HPV-associated diseases. However, unlike high-risk E6, expression of low-risk HPV E6 in 782 
C33A cells did not augment the sensitivity of these cells to CDV. The authors conclude from their studies that 783 
CDV may have little selectivity for low-risk HPV related diseases. However, they based their conclusion only on 784 
the expression of one of the viral oncoproteins neglecting the fact that low-risk HPV lesions are due to HPV-785 
induced hyperproliferation resulting from productive HPV infection. On the other hand, Donne’s experiments 786 
presumably used newly transfected E6 and E7 expression vectors that had not replicated in the presence of CDV 787 
and therefore would not have incorporated CDV to block transcription. On the other hand, they tested the 788 
effects of CDV on expression of HPV6b and HPV16 E6 mRNA levels in a system that over-expresses these viral 789 
proteins. Also, they used the cervical carcinoma HPV-negative cell line C33A which is also sensitive to the 790 
antiproliferative effects of CDV. In contrast to previous results, they found increased HPV E6 RNA levels in C33A 791 
cells that over-expressed HPV6b or HPV16 E6 and no selectivity of CDV for HPV-positive cells (Donne et al., 792 
2009,Donne et al., 2007). 793 
A crucial difference between normal keratinocytes, benignly HPV-infected cells, and immortalized or 794 
transformed cells is the frequency as well as level of induction of host enzymes associated with energy 795 
metabolism and with S-phase entry and cell cycle progression to G2 phase, driven by the PyV LT-ag or the PV E7 796 
protein. Notably, the DNA viruses strongly up-regulate glycolysis including kinases such as pyruvate kinase. It can 797 
be hypothesized that phosphorylation of CDV and other ANPs might be selectively activated in this productive or 798 
transformed environment compared to more quiescent normal cells. Accordingly, to explain the selectivity of 799 
CDV for HPV-positive cells, Johnson and Gangemi (Johnson and Gangemi, 1999) claimed that CDV could be 800 
differentially metabolized in HPV-positive cells and normal keratinocytes. Following 8 and 16 hours incubation, 801 
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CDV was found to predominantly accumulate in the form of CDVp-choline (considered the intracellular depot 802 
form of CDV) in human primary keratinocytes (PHKs) while in HPV16-transformed keratinocytes, CDVpp was the 803 
most abundant anabolic product with little CDVp-choline having formed.  804 
Recently, we reported that following 72 h incubation with CDV, CDVp-choline appeared to be the most 805 
abundant metabolite while the monophosphate form was the least abundant one in PHKs as well as in HPV-806 
positive and HPV-negative tumor cells (De Schutter et al., 2013c). Importantly, no significant differences in the 807 
levels of the active metabolite CDVpp, CDVp-choline or CDV were observed between PHKs and HPV-positive 808 
tumor cells. However, lower CDVp levels were measured in PHKs compared to HPV-positive cells following 72 h 809 
incubation. Notably, lower concentrations of CDV and of all metabolites were observed in the spontaneously 810 
transformed keratinocyte cell line HaCaT that lack HPV sequences, compared to either HPV-positive cells or 811 
PHKs, suggesting that HaCaT cells have a different uptake and/or efflux of CDV, rather than differences in drug 812 
metabolism. 813 
To reveal the molecular mechanisms underlying the selectivity of CDV for tumor cells, in particular for HPV-814 
positive carcinoma cells, our research team evaluated gene expression changes following CDV treatment of 815 
different cell types [including two HPV-positive cervical carcinoma cell lines (SiHa, HPV16+ and HeLa HPV18+), an 816 
HPV-immortalized keratinocyte cell line (HaCaT), and PHKs (De Schutter et al., 2013c). In addition, drug 817 
incorporation into genomic DNA was analysed in the four cell types. An exhaustive and thorough analysis of the 818 
microarray data highlighted distinct responses to CDV exposure in PHKs compared to HPV-positive cervical 819 
carcinoma cells, on the one hand, and to HPV-immortalized keratinocytes, on the other hand. Our data indicated 820 
that the selectivity of CDV for HPV-transformed cells is based on differences in response to DNA damage, 821 
replication rate and CDV incorporation into cellular DNA between immortalized cells and normal cells, rather 822 
than on a specific effect of CDV on expression of the viral oncoproteins (De Schutter et al., 2013c). Normal cells 823 
possess an arsenal of repair pathways and cell cycle checkpoints to detect and repair DNA damage unlike 824 
transformed cells that have a significantly reduced set of DNA repair pathways for survival (Figure 3A).  825 
The presence of E6 and E7 appears to indirectly contribute to the efficacy and selectivity of CDV because the 826 
role of E7 interactions with host cell cycle control proteins is (a) to reactivate cell cycle (notably S-phase) in 827 
differentiated cells that had withdrawn from the cell cycle, and (b) to trigger unscheduled DNA synthesis.  As a 828 
consequence, E7 quickly leads to the stabilization of p53 and hence the need for E6:E6AP to neutralize p53 or 829 
lead to its ubiquitinylation and proteasome-mediated turnover. 830 
 The selective mechanism of action of CDV as antiproliferative agent could be inferred by analyzing the 831 
specific signatures identified in CDV-exposed PHKs that were not found in tumor cells, including cell cycle 832 
regulation and activation of DNA-double strand breaks (DSBs) repair mechanisms (i.e. ‘ATM Signalling’ and 833 
‘Double-Strand Break Repair by Homologous Recombination’) (Figure 3B). These findings suggest that CDV can 834 
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generate double-strand DNA breaks that cannot be repaired by tumor cells but well by normal cells (De Schutter 835 
et al., 2013c).  836 
Furthermore, when we compared the efficiency of CDV incorporation into genomic DNA in the different cell 837 
types, higher amounts of CDV were incorporated in the genomic DNA of transformed epithelial cells compared 838 
to PHKs, despite the fact that the levels of intracellular CDV metabolites were not significantly different among 839 
the cell types investigated. Recently, these findings were confirmed by P. Hadaczek and co-workers who also 840 
found that CDV is incorporated into cellular DNA activating DNA damage response pathways due to increased 841 
DNA breaks that prompt elevated tumor cell apoptotic response in glioblastoma cells (Hadaczek et al., 2013).  842 
Besides differences in cell cycle regulation and DNA repair pathways, our gene expression profiling analysis 843 
also allowed the identification of other pathways and functions that were induced or repressed following 844 
exposure to CDV differently in PHKs compared to HPV-positive and/or HPV-negative cells (De Schutter et al., 845 
2013c). For instance, Rho GTPase pathways and the acute phase response pathway were solely activated in 846 
immortalized cells while normal keratinocytes showed the activation of several metabolic pathways (Figure 4). 847 
Therefore, besides induction of double-strand DNA breaks, CDV showed a differential effect on specific 848 
pathways in normal cells compared to transformed cells that may contribute to the activity and selectivity of the 849 
drug for tumor cells.   850 
Furthermore, in vitro acquisition of resistance to CDV in SiHa cells was found to implicate a variety of cellular 851 
functions and pathways linked to cell death, cell growth and differentiation, cellular movement, metabolism, 852 
tissue development as well as inflammatory response (De Schutter et al., 2013b). Notably, SiHa cells selected for 853 
resistance to CDV presented a reduced growth in vitro and in the mouse xenograft model inducing a reduced 854 
inflammation, as measured by a reduced production of mice- and human-derived cytokines, diminished effect 855 
on chemical and haematological blood parameters, lower number of cells in the spleen and lesser splenomegaly 856 
compared to parental cells. Interestingly, when parental and CDV-resistant cells produced an equivalent size of 857 
xenografts (i.e. 3 and 5 weeks post cell-inoculation), the amount of neutrophils, macrophages, NK cells and 858 
inflammatory cytokines was significantly higher in the animals inoculated with the parental cells compared to 859 
those that received the CDV-resistant cells. 860 
 861 
7. Extension of the clinical use of CDV for the treatment of tumors not induced by oncogenic viruses 862 
Our data obtained by whole genome gene expression profiling of normal versus immortalized cells exposed 863 
to CDV supports the use of CDV for the treatment of non-viral induced neoplasias. Furthermore, a few reports 864 
sustain this hypothesis. For instance, CDV proved effective in reducing the growth of melanoma B16 in an 865 
experimental model in mice (Redondo et al., 2000). The most effective treatment in this model was 866 
subcutaneous administration of 67 mg/kg on alternative days three times weekly that resulted in 90% inhibition 867 
of tumor growth.  868 
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When CDV antiproliferative effects were evaluated against a series of nine HPV-negative cells, the 50% 869 
cytostatic concentrations of the drug following 7 days of incubation varied between 1.4 µg/ml (for the cervical 870 
carcinoma cell line C33A) and 43 µg/ml (for the breast carcinoma cell line BT-20) compared to 0.7 to 2.0 µg/ml 871 
for four different HPV-positive cell lines [SiHa and CaSki (HPV-16), HeLa (HPV-18) and CK-1 (HPV-33) (Andrei et 872 
al., 1998a). When ODE-CDV was compared to CDV, ODE-CDV proved more potent than the parent compound 873 
against the HPV-positive cell carcinoma cell lines HeLa, CaSki, Me-180 (HPV-68) and the C33A cervical carcinoma 874 
cells lacking HPV (Hostetler et al., 2006).  875 
Liekens et al have demonstrated the inhibitory effects of CDV on the development of virus-independent 876 
vascular tumors originated by basic fibroblast growth factor (FGF2)-overexpressing endothelial cells (FGF2-T-877 
MAE). The in vivo antitumor efficacy of CDV was attributed to specific induction of apoptosis in this model 878 
(Liekens et al., 2007). In addition, CDV treatment of FGF2-T-MAE cells resulted in a pronounced up-regulation of 879 
the tumor suppressor protein p53. However, the expression of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) 880 
proteins remained unchanged, and CDV did not induce the release of cytochrome c from the mitochondria. 881 
Therefore CDV appeared to inhibit the growth of FGF2-T-MAE cells via inhibition of FGF2 expression and 882 
signalling (Liekens et al., 2007). 883 
Recently, it was shown that CDV possesses potent antineoplastic activity against both HCMV positive and 884 
negative glioblastomas (Hadaczek et al., 2013). While this activity was associated with inhibition of HCMV 885 
expression and with activation of cellular apoptosis in HCMV-positive glioblastomas, CDV was also demonstrated 886 
to induce cell death in the absence of HCMV. CDV incorporated into tumor cell DNA promoting double-strand 887 
DNA breaks and apoptosis.  888 
 889 
8. Can the antitumor activity of CDV be synergized? 890 
Considering the mode of cell killing by CDV, combination of CDV and radiation therapy can be considered as a 891 
promising and feasible strategy to improve treatment outcomes for different tumor types, of both viral and non-892 
viral origin.  893 
By the addition of further DNA damage, such as irradiation therapy, it can be hypothesized that cellular 894 
apoptotic response to CDV would increase. Indeed, combining CDV with irradiation both in vitro and in 895 
engrafted nude mice resulted in a marked radio-sensitization in HPV-positive cells, which was not observed in 896 
HPV-uninfected cells (Abdulkarim et al., 2002). The synergistic effect of CDV and radiation in HNSCC cells was 897 
associated with p53 accumulation. It has also been shown that the combination of CDV and radiation had a 898 
potent anti-angiogenic effect, inducing inhibition of E6 expression, restoration of p53, and reduction of the pro-899 
angiogenic phenotype of HPV18 positive cells associated with VEGF (vascular endothelial growth factor) 900 
inhibition (Amine et al., 2006).  CDV also enhanced the radiation-induced apoptosis in EBV-positive cells and in 901 
EBV-related cancer xenografts (Abdulkarim et al., 2003). CDV induced a downregulation of the EBV oncoprotein 902 
28 
 
LMP1 associated with a decrease in expression of the anti-apoptotic Bcl-2 protein and an increase of the pro-903 
apoptotic Bax protein in Raji (Burkitt lymphoma) and C15 (nasopharyngeal carcinoma) cells (Abdulkarim et al., 904 
2003).  905 
The antitumor effect of CDV was also evaluated in combination with radiation therapy against glioblastoma 906 
(Hadaczek et al., 2013). In vitro, a dramatic increase (over 21-fold) of phosphorylated H2AX, an indicator of DNA 907 
damage/instability, after exposure to both CDV and ionizing radiation was observed. Furthermore, this 908 
combination resulted in reduced tumor growth in a model of human glioblastoma-derived intracranial 909 
xenografts in mice leading to increased animal survival.  910 
On the other hand, the combination of cidofovir with chemotherapeutics presenting a different mode of 911 
antitumor action may be expected to result in synergistic antitumor activity. In line with this assumption, 912 
Deberne and colleagues investigated the combination of cidofovir with the anti-epidermal growth factor 913 
receptor monoclonal antibody cetuximab in vitro (using a clonogenic survival assay, cell cycle analysis, and 914 
phospho-H2AX levels) and in vivo (using xenograft models) (Deberne et al., 2013). This combination was 915 
assessed considering the cross-talk between epidermal growth factor receptor and HPV that is implicated in 916 
tumor progression. The CDV-cetuximab combination inhibited the growth of the different cell lines tested, 917 
including HPV-positive (HeLa and Me 180) and HPV-negative (C33A, H460 and A549) cells, with synergistic 918 
activity on HPV-positive but not on HPV-negative cells. The CDV-cetuximab combination also delayed tumor 919 
growth of HPV-positive tumors in vivo but no efficacy was reported on HPV-negative C33A xenografts. The 920 
combination induced S-phase arrest associated with enhanced levels of double-strand breaks (as measured by 921 
phosphorylation of H2AX) in HeLa and Me 180 cells.  922 
 923 
9. Conclusions and Perspectives 924 
The research performed in the last years has provided a better understanding on the mechanisms of 925 
antitumor efficacy of ANPs. Although comparative studies between CDV and ANPs of the PME series (such as 926 
PMEG) are missing, their action on cellular DNA polymerization appeared to be different, PMEG having a higher 927 
affinity for cellular DNA polymerases than CDV. An important difference between both drugs is the ability of 928 
PMEG to cause chain termination of viral DNA synthesis in contrast to CDV that can be incorporated. Although 929 
both PMEG and CDV can cause DNA damage, they may differ in the type of damage induced. In the case of CDV, 930 
it appeared that the drug is able to induce double-stranded DNA damage and that only normal cells are capable 931 
of activating a DNA damage response and repair the damage via homologous recombination (considered as a 932 
very faithful mechanism of DNA repair). On the other hand, it appears that CDV is able to trigger several 933 
signalling pathways in tumor cells, both HPV-positive and HPV-negative cells, such as Rho GTPase signalling and 934 
acute phase response that may also contribute to its antitumor efficacy and selectivity. 935 
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There is an unmet need for effective anti-HPV treatments for existing infections and for patients that do not 936 
receive the prophylactic vaccination. Also, no FDA-approved treatments exist to manage human PyV infections.  937 
The use of cidofovir derivatives such as CMX001 (with substantially improved oral bioavailability and reduced 938 
toxicity compared to CDV) and HPMP-5-azaC (with in vitro and in vivo antiproliferative effects equivalent as 939 
those described for CDV) deserve further evaluation. Also, the use of formulations of CDV should be envisaged in 940 
order to use lower drug levels and enhance efficacy. A recent study has shown that formulation of CDV 941 
improved the anti-papillomavirus activity of topical CDV treatments in the CRPV/rabbit model (Christensen et 942 
al., 2014). 943 
Importantly, CDV was suggested to affect the LT-ag of PyV, indicating that the helicase activity associated 944 
with the LT-ag may be the target of CDV. Although there is no overall homology among the PyV and PV 945 
genomes, the helicase motif of PV E1 protein, a domain stretching about 230 amino acids, has some sequence 946 
similarity with the SV40 LT-ag (de Villiers et al., 2004). Furthermore, a comparison of the active s                                        947 
ite from SV40 LT-ag and HPV E1 proteins shows high similarities (Figure 5). The lysine finger is conserved in the 948 
LT-ag and the HPV E1 proteins and, in addition, a number of aspartates, asparagines and threonines are 949 
conserved in the active site of both types of proteins. Structural similarities between the LT-ag and the BPV E1 950 
protein have also been described (Topalis et al., 2013). This opens new perspectives in the understanding of the 951 
mechanism of inhibition by CDV during productive PyV and HPV replication as the E1 HPV protein also has 952 
helicase activity. Various validated systems for testing the components of HPV E1 helicase and viral DNA 953 
replication using transient transfection of E1 and E2 expression plasmids or using purified enzymes in vitro have 954 
been reported (Liu et al., 1995,Kuo et al., 1994,Fradet-Turcotte et al., 2010).   955 
Further research is also needed in understanding the effects of CDV on the productive replicative cycle of 956 
low-risks HPVs and the organotypic epithelial raft cultures appear to be the ideal system to perform these 957 
investigations as they reproduce epithelial differentiation in an ex vivo system. A fully productive 3-dimensional 958 
tissue culture system for production of high yields of infectious HPV-18 virions was first described in 2009, with 959 
multiple published applications since then (Wang et al., 2009). 960 
This system appears to be also more appropriate to analyze drug-metabolism because nucleoside 961 
metabolism in cell monolayer cultures (especially with immortalized and transformed cells) are considerably 962 
abnormal compared to 3-dimensional tissues, where most cells are quiescent. Moreover, uptake of small 963 
molecules is substantially altered in rapidly dividing monolayer cells that do not have cell-cell junctions. 964 
Nucleotide synthetic pathways have exquisitely coordinated balancing of de novo production of the 965 
ribonucleoside and the deoxyribonucleoside triphosphates, and these regulatory responses are also heavily 966 
influenced by salvage of nucleosides from broken down RNA and DNA or from the general circulation. 967 
Exogenous agents such as inhibitors of these synthetic or salvage pathways (eg. hydroxyurea, methotrexate) or 968 
from nucleoside analogs (eg. 5-FU) can substantially alter this balancing network.  Whether CDV or other ANP's 969 
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have an impact on the normal distribution of ribo- and deoxyribo-nucleosides and their phosphorylated 970 
derivatives should be investigated.  How CDV and other ANPs impact ribonucleoside diphosphate reductase, the 971 
main source of deoxynucleotide synthesis in virally infected cells should be considered, as well as the 972 
consequences of cell growth in the presence of CDV with respect to ribosomal RNA transcription and processing.  973 
 One of the major findings regarding CDV-antitumor activities points to the potential use of the drug in the 974 
therapy of non-viral induced tumors such as glioblastomas. Also, further research will be necessary to elucidate 975 
the effects of CDV in several signalling pathways compared to PME derivatives and other chemotherapeutics in 976 
order to highlight (dis)similarities and understand their mechanisms of action. 977 
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 1002 
Legends to the figures 1003 
Figure 1. Intracellular metabolism of CDV and mechanism of action against viruses encoding for their own 1004 
DNA polymerases. Once inside the cells, CDV needs to be activated by cellular enzymes (Ho et al., 1992). UMP-1005 
CMP kinase catalyses the conversion of CDV to CDV-monophosphate (CDVp), which is then further 1006 
phosphorylated to the active form, CDV-diphosphate (CDVpp) by nucleoside 5‘-diphosphate kinase, pyruvate 1007 
kinase or creatine kinase. CDVpp can be used by the choline phosphate cytidyltransferase to form the CDVp-1008 
choline according to the reaction : CDVpp + choline phosphate → CDVp -choline + pyrophosphate (Cihlar and 1009 
Chen, 1996). Choline-phosphate cytidylyltransferase (EC 2.7.7.15) is an enzyme that catalyzes the chemical 1010 
reaction CTP + choline phosphate   diphosphate + CDP-choline where the two substrates of this enzyme are 1011 
CTP and choline phosphate, and the two products are diphosphate and CDP-choline. Choline phosphate 1012 
cytidyltransferase is responsible for regulating phosphatidylcholine content in membranes. CDVp-choline is 1013 
considered to serve as an intracellular reservoir for the mono- and diphosphate derivatives of CDV. The active 1014 
form of CDV (i.e. CDVpp) interacts with the viral DNA polymerase as either competitive inhibitor [with respect to 1015 
the natural substrates (i.e. dCTP)] or alternative substrate (thus leading to incorporation into DNA). CDV has a 1016 
hydroxyl function in the acyclic side chain that would allow further chain elongation. For human CMV, chain 1017 
termination occurs when two consecutive CDVpp are incorporated in the growing DNA chain. 1018 
 1019 
Figure 2. Scaffold of PME and HPMP derivatives. Chemical structures of PME and HPMP derivatives that are 1020 
known for their antiproliferative activities. Chemsketch has been used to draw the structures of the different 1021 
drugs. 1022 
 1023 
Figure 3. (A) Differential response of normal cells and cancer cells to DNA damage. Adapted from (Khalil et al., 1024 
2012). Lines with arrow head indicate activation, while lines with bar head indicate inhibition. In response to 1025 
DNA damage, normal cells activate the DNA damage response pathway which will cause G1/S arrest via the p53 1026 
pathway and G2/M arrest via checkpoint kinases Chk1 and Chk2 pathway. In normal cells, cell cycle arrest by 1027 
either of these pathways allows time for DNA repair resulting in the prevention of genomic instability. In 1028 
contrast, cancer cells have a dysfunctional G1/S checkpoint because of loss of p53 function. In addition, most of 1029 
the tumor cells present alterations in the ATM pathway leading to disruption of the G2/M checkpoint. As a 1030 
result, cancer cells will accumulate irreparable lesions resulting in the activation of apoptosis. (B) Differential 1031 
response of normal cells and tumor cells to CDV. According to the microarray data reported by (De Schutter et 1032 
al., 2013c), primary human keratinocytes (PHKs) activate cell cycle regulation mechanisms that allow DNA repair 1033 
by means of homologous recombination (HR), leading to genomic stability and cell survival. Complete lines with 1034 
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arrow heads indicate activation while dashed lines indicate alternative repair pathways that were not identified 1035 
in the microarray data. In contrast to normal cells, the immortalized keratinocyte cell line HaCaT and the cervical 1036 
carcinoma cell lines SiHa (HPV16) and HeLa (HPV18) are unable to repair DNA damage resulting in genomic 1037 
instability and induction of apoptosis. The most relevant genes related to cell cycle regulation and/or DNA 1038 
damage repair pathways found upregulated following CDV exposure of PHKs are shown in red.  1039 
 1040 
Figure 4. Differential response to CDV treatment of HPV-positive and HPV-negative immortalized 1041 
keratinocytes versus primary keratinocytes based on a whole genome gene expression profile reported by (De 1042 
Schutter et al., 2013c). Activation of several metabolic, cell cycle regulation and DNA repair pathways were 1043 
solely activated in normal keratinocytes while immortalized cells failed to induce DNA repair mechanisms 1044 
following exposure to CDV. Importantly, two pathways (i.e. ‘activation of Rho GTPase signaling’ and ‘acute phase 1045 
response signaling’) were exclusively identified in CDV-treated immortalized cells. 1046 
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Table 1. Clinical uses of CDV (as an antiviral and antiproliferative agent) either approved [by the Food and 1588 
Drug Administration (FDA)] or supported by clinical data (De Clercq, 2003,Snoeck and De Clercq, 2002,De 1589 
Clercq, 2006,De Clercq, 2011).  1590 
 1591 
Route of administration Clinical indication 
Systemic (intravenous) 
 
• HCMV retinitis in AIDS patients (approved). 
• HSV-1, HSV-2 and VZV infections (particularly those that are 
resistant to acyclovir and/or foscavir). 
• HCMV infections, mainly those resistant to ganciclovir due to 
mutations in the UL97 gene. 
• EBV, HHV-6, HHV-7 and HHV-8 (Kaposi’s sarcoma associated 
herpesvirus) infections. 
• Polyomavirus infections due to JCPyV [progressive multifocal 
leukoencephalopathy (PML)] and polyoma BKPyV [hemorrhagic 
cystitis]. 
• Systemic adenovirus infections. 
Systemic (intravenous) or topical 
(gel/cream) 
• Molluscum contagiosum, orf and other poxvirus infections such as 
monkeypox and smallpox.  
• Complications of smallpox vaccine (vaccinia). 
Topical (gel/cream) • Mucocutaneous HSV-1 or HSV-2 infections (particularly those resistant to acyclovir and/or foscavir. 
Topical (eyedrops) • Keratoconjunctivitis due to HSV or adenovirus. 
Topical (intravitreal) • HCMV retinitis. 
Topical (gel/cream), intralesional 
injection, infrequently systemic 
administration) 
• Human papillomavirus-associated lesions: 
- recurrent laryngeal papillomatosis 
- anogenital warts 
- common warts 
- cervical/vulvar/anal/penile intraepithelial neoplasia 
Herpes simplex 1 (HSV-1) and 2 (HSV-2), human cytomegalovirus (HCMV), varicella-zoster virus (VZV), human 1592 
herpesvirus 6 (HHV-6), 7 (HHV-7), 8 (HHV-8). Foscavir: foscarnet sodium injection. 1593 
 1594 
 1595 
 1596 
  1597 
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Table 2. Major similarities and differences between polyoma- and papillomaviruses. 
 Polyomavirus Papillomaviruses 
Genome • Double-stranded 
• Circular 
• DNA 
• ∼5 kbp 
• Uses overlapping genes and both strands 
of DNA to pack all 6 genes into 5 kbp 
• Double-stranded 
• Circular 
• DNA 
• ∼8 kbp 
• Uses overlapping genes and one strand of 
DNA to pack all 7 genes into 8 kp 
Morphology • Non-enveloped 
• ∼ 45 nm diameter 
• Icosahedral, T=7 
• 3 capsid proteins (VP1, VP2, VP3) 
• Non-enveloped 
• ∼ 52-55 nm diameter 
• Icosahedral, T=7 
• 2 capsid proteins (L1, L2) 
Early proteins • LT-ag 
• sT-ag 
• mT-ag (in murine PyV) 
• ALTO (in TSPyV) 
 
• E1: viral replication 
• E2: viral replication and transcription 
• E4: desestabilization of cytokeratin 
network 
• E5: alteration of growth factor signaling 
• E6: oncoprotein 
• E7: oncoprotein 
DNA Replication • LT-ag is the multifunctional initiator 
protein 
 
• The C-terminal domain of LT-ag have 
ATPase/helicase activity and is sufficient 
for oligomeriation into hexamers 
• The central part of LT-ag contains an origin-
binding domain (OBD) which recognizes 
specific sequences in the origin 
 
 
• The LT-ag OBD can bind with high-affinity 
to its target binding site as a monomer  
• Specific N-terminal domain of LT-ag that 
contains a unique J-domain, a monopartite 
nuclear localization signal (NLS) and several 
phosphorylation sites for different kinases 
that modulate either the nuclear import of 
LT-ag or its assembly into a double 
hexamer at the origin 
• E1 is the multifunctional initiator protein 
but also requires E2 to initiate viral 
replication in vivo 
• E1 requires interaction with E2 to 
oligomerize into hexamers 
 
• Replication begins with the recruitment of 
E1 by E2 to the Ori and requires an 
essential protein-protein interaction 
between the E2 transactivating domain 
(i.e. TAD) and the E1 helicase domain  
• The E1 OBD needs to dimerize to bind with 
high-affinity to its target binding site  
• Specific N-terminal domain of E1 that 
contains a bi-partite NLS, a Crm1-
dependent nuclear export signal (NES), and 
a binding site for cyclin A/E-cdk2 and 
several phosphorylation sites for different 
kinases that modulate either the nuclear 
import of LT-ag or its assembly into a 
double hexamer at the origin 
Interaction with 
tumor suppressor 
proteins  
• The LT-ag binds to both Rb family proteins 
and p53. 
• E6 binds to p53 and other pro-apoptotic 
proteins and E7 binds to Rb family proteins 
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Table 3.  Comparison of the ATP binding site from SV40 LT-ag and HVP-16/18/6 E1. The ATP binding site is formed from 
residues belonging to two adjacent monomers (cis- and trans-domains). The P-loop (sequence G(X)4GKT/S) is a motif 
present in all the proteins harboring an ATP binding site. 
² 
Polyomavirus High Risk HPV Low Risk HPV 
ATP binding domain SV40 LT-ag HPV-16 E1 HPV-18 E1 HPV-6 E1 
Trans-domain 
K418-K419 
R498, D502, R540 
K469-K470 
R537, D541, R581 
K476-K477 
R544, D548, R589 
K470-471 
R538, D542, R582 
Cis-domain D474, N529 D523, N567 D530, N574 D524, N568 
P-loop 426-GPIDSGK-432 477-GAANTGK-483 484-GPANTGK-490 478-GPPDTGK-484 
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Box 1. 
 
 
Polyomavirus (PyVs) genome organization. The PyV genome is functionally divided into coding (early and late) and non-coding 
regions. In all PyVs, the early coding region encodes for the Large T antigen (LT-ag) and small T antigen (sT-ag) while the late 
region encodes for the viral structural proteins and the non-structural agnoprotein, which is exclusively found in BKPyV and 
JCPyV (Khalili et al., 2005). Agnoproteins contribute to viral propagation at various stages in the replication cycle, including 
transcription, translation, processing of late viral proteins, assembly of virions, and viral propagation. The non-coding control 
region (NCCR) contains the viral promoters and origin of replication. The late region encodes the viral capsid proteins VP1-3 and 
the recently discovered VP4 in SV40. VP1 forms 72-pentameric capsomers, each capsomer containing a single copy of the minor 
structural protein VP2 or VP3 in its central cavity. VP4 is expressed during the late stages of SV40 replication and is not found in 
the virion. SV40 appears to initiate cell lysis by expression of VP4 which acts as a viropin that form pores resulting in perforation 
of cellular membranes for virus release (Raghava et al., 2011,Raghava et al., 2013).  The JCPyV agnorpotein was also shown to 
act as a viropin (Suzuki et al., 2010). 
 
 
 
Merkel cell polyomavirus (MCPyV) integration in Merkel cell carcinoma (MCC), adapted from (Moore and Chang, 2010). In 
case a rare integration mutation into the host cell genome occurs, the MCV T antigen can activate independent DNA replication 
from the integrated viral origin, which would result in replication fork collision and DNA fragmentation. Hence, a second 
mutation in the LT-ag that eliminates its replication functions upon integration is required for tumorigenesis. All MCC-derived 
LT-ag sequences analyzed so far present premature stop codons or deletions leading to abrogation of the helicase domain. 
These mutations are specific for MCPyV in MCC and are absent in viruses derived from non-tumor tissues. The truncation 
mutations eliminate LT-ag helicase activity but retain the LXCXE–retinoblastoma protein-binding motif as well as other N-
terminal motifs of the LT-ag. Thus, the integrated virus in MCC retains the ability to regulate the host cell cycle and inhibit the 
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Box 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic presentation of the closed circular double-stranded human papillomavirus (HPV) DNA and its integration into 
host-cell DNA. Adapted from (Stanley et al., 2007). In the circular HPV genome are shown the non-coding region (i.e. long 
control region) and the open reading frames (ORFs) encoding the early and late viral proteins. During the process of 
oncogenesis, the viral genome becomes integrated into host cellular DNA. The circular HPV DNA is usually opened within 
the E2 ORF, disrupting its continuity. Part of E2, E4, E5 and L2 are regularly deleted after integration (partial genes are 
represented by an asterisk).  
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Box 3 
 
 
 
 
Scheme of the polyomavirus replicative cycle. To gain entry into the cells, viral capsid proteins interact directly with the 
receptor molecules. The PyV capsids consist of 72 pentamers of the major capsid protein viral protein 1 (VP1), which is 
responsible for antigenicity and receptor specificity. PyVs are internalized by the interaction of VP1 with specific cellular 
receptors. Gangliosides [glycosphingolipids (ceramide and oligosaccharide) with one or more sialic acids (n-acetylneuraminic 
acid, NANA) linked on the sugar chain] are used as receptors for most of the well-characterized polyomaviruses.  For instance, 
gangliosides GD1a and GT1b are recognized as receptors for murine PyVs and GM1 for SV40 (Ashok and Atwood, 2006). In the 
case of BKPyV, it was shown that the virus uses specific gangliosides that all contain a common α2,8-disialic acid motif to infect 
the cells (Neu et al., 2013). Lactoseries tetrasaccharide c (LSTc) which terminates in α2,6-linked sialic acid was identified as the 
specific receptor for JCPyV and the presence of α2,6-linked sialic acid correlates with JCPyV cell and tissue infection, including B 
lymphocytes, kidney, and the glial cells astrocytes and oligodendrocytes (Hirsch et al., 2013,Maginnis et al., 2013). PyVs enter 
into the host cell via a caveolae-mediated endocytic pathway (Tsai and Qian, 2010). In contrast to most PyVs, JCPyV 
internalization relies on clathrin-dependent receptor-mediated endocytosis and is then sorted to caveosomes.  Trafficking 
through the endoplasmatic reticulum (ER) appears to be a necessary step for all PyVs (Bennett et al., 2012). The presence of 
chaperons, disulfite isomerases and reductases in the ER may facilitate the capsid uncoating process. The viral genome, still 
associated with some viral proteins, is imported into the nucleus via importin recognition of a nuclear localization signal 
present in VP3. In the nucleus, early genes are expressed by the host transcriptional machinery (Fanning et al., 2009,Hirsch et 
al., 2013). After translation of the early proteins, the LT-ag initiates DNA replication of the viral genome that is carried out by 
cellular DNA polymerases. The shift to transcription of late genes is not completely elucidated but involves transcriptional 
activation of the late and repression of the early promoters by LT-ag. The constitutive viral capsid proteins are imported to the 
nucleus where encapsidation of the viral genomes occur followed by release of new virions. 
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Box 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional domains of polyomavirus (PyV) Large T antigen (LT-ag). Adapted from (DeCaprio and Garcea, 2013). The N 
terminus of LT-ag contains a DnaJ domain (or J domain), necessary for efficient viral DNA replication, recruits heat shock 
cognate protein (HSC70) homologues. Besides the DnaJ domain, all LT-ag’s contain a LXCXE motif that binds directly to the 
tumour suppressor retinoblastoma protein family of proteins (i.e. pRb, p130 and p107). The DnaJ domain and the LXCXE motif 
cooperate to disrupt the interaction of Rb and the E2F family of transcription factors in order to promote cell cycle 
progression. The LT-ag of all PyVs also contain a threonine-proline-proline-lysine (TPPK) motif, a nuclear localization signal 
(NLS), a DNA-binding domain (DBD) and a helicase domain. Phosphorylation of the threonine residue in the TPPK motif is 
required for LT-ag-mediated viral DNA replication. The DBD and helicase domains are required for viral replication and recruit 
cellular DNA replication factors [DNA polymerase-α catalytic subunit (POLA), the replication protein A complex (RPA) and the 
DNA primase complex (PRIM) for DBD and EP300, CREBBP, p53 and DNA topoisomerase (TOP1) for the helicase domain]. The 
outside surface of the helicase domain of PyVs binds to the tumor suppressor protein p53, blocking p53-dependent gene 
expression in response to DNA damage signals. After the helicase domain, the C-terminal region of JCPyV and BKPyV contains a 
C-terminal region that bears some homology with the SV40 C-terminal domain. This region of homology includes threonine-
701 in SV40 that when phosphorylated competes with phosphorylated cyclin E and MYC, increasing their levels and in this way 
contributing to cellular growth and proliferation. The C-terminal region of SV40 also binds to FAM111A known to contribute to 
viral gene expression, host range restriction and adenovirus replication. Except for JCPyV and BKPy V, all the human 
polyomaviruses LT-ag’s contain much shorter C-terminal region with little homology among them or with SV40. 
 
   
Mechanism of DNA unwinding by the LT-ag. Adapted from (Trakselis and Graham, 2012). LT-ag binds to the origin of 
replication as a double hexamer which then splits into two single hexamers. Each hexamer tracks along a “leading” strand in 
the 3’-to-5’ direction while excluding the other “lagging” strand, unwinding double-stranded DNA as they go. If the hexamers 
encounter a protein covalently attached, they can bypass it efficiently without dissociating from the DNA (Yardimci et al., 
2012). 
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Box 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell cycle regulation. The transcription factor p53 responds to diverse stresses, including DNA damage, regulating many target 
genes that induce cell-cycle arrest, apoptosis, senescence, DNA repair or altered metabolism. The tumor suppressor protein p53 
prevents cells from entering to or progressing through the cell cycle under conditions that could cause DNA damage. p53-functions 
in the cell cycle include the control of the G1 transition to the S phase of the cell cycle at the G1 checkpoint by inducing expression 
of cyclin inhibitors p16, p21 and p27 that block the activities of cyclin-cyclin-dependent kinase (CDK) complexes, thus mediating 
arrest of the cell cycle by blocking the progression of the cell cycle at the G1/S transition. Because of the central role of p53 in life or 
death decisions, an exquisite control mechanism of p53 exists. Central to this regulation are the essential p53 inhibitors MDM2 and 
MDM4, although other participants in p53 control have been described although they are not shown in this figure. In normal cells, 
Mdm2 and Mdm4 (also called Mdmx; human orthologues often referred to as HDM2 and HDM4/HDMX, respectively) are key 
regulators of the tumor suppressor protein p53 (MDM2 mainly regulates p53 stability while MDM4 has a major role in regulating 
p53 activity). DNA damage induces MDM2 self-degradation and an MDM2-dependent degradation of MDM4, a process essential to 
mount a p53 response.  
 
 
 
Deregulation of the cell cycle by polyoma- and papillomaviruses. Initially, polyomavirus LT-ag binds to products of the RB-family of 
proteins thereby interfering with their activity and inducing the infected cell to enter the cell cycle S phase. Subsequently, the LT-ag 
inactivation of p53 allows re-phosphorylation of Rb proteinsthrough the cyclin dependent kinase (cdk) pathway and prevents the 
p53-mediated apoptosis of the infected cell. In HPV, Inactivation of p53 by the high-risk E6 proteins results in abrogation of growth 
arrest and pro-apoptotic effects of p53 whose levels increase due to the constitutive E2F gene transcription as a consequence of 
inactivation of Rb proteins by the E7 oncoprotein. 
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Box 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme of the life cycle of human papillomaviruses. Adapted from (Moody and Laimins, 2010). Following exposure through 
microwounds, keratinocytes in the basal layer of the epithelium are infected by HPV. The infected epithelium (on the right) is 
compared to the uninfected epithelium (on the left). Following infection, viral genomes are maintained in the nucleus as low 
copy numbers in an episomal state and they are replicated together with the cellular DNA. Early viral genes are expressed. 
Following cell division, one daughter cell leaves the basal layer undergoing differentiation and this process of differentiation 
induces the productive phase of the viral life cycle. In order to activate the cellular DNA synthesis machinery, the viral E6 and E7 
proteins are expressed which are responsible for deregulation of the cell cycle control, pushing the differentiating cells to enter 
into S phase of the cell cycle. Viral genome replication occurs then in cells that normally would have undergone terminal 
differentiation. The late proteins L1 and L2 are synthesized only in the upper layers of the epithelium and are assembled 
together with the viral genomes to form virions that are released at the surface of the epithelium. 
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Box 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 8 
 
Schematic representation of E1 and E2 proteins. Adapted from (D'Abramo and Archambault, 2011). E1 and E2 are about 650 and 370 
amino acids long and are necessary for replication of the viral genome. Three functional domains are recognized in E1: a C-terminal 
ATPase/helicase domain that can oligomerize into hexamers, a central origin DNA-binding domain (OBD), and an N-terminal regulatory 
region which is essential for optimal replication in vivo but not in vitro. The N-terminal region consists of conserved sequences for 
nuclear localization (NLS), nuclear export (NES) and a conserved cyclin-binding motif. E1 functions as a DNA binding protein to 
recognize the viral origin and also as a helicase to unwind DNA. E1 is also responsible for the recruitment of cellular proteins to the 
origin of replication. The E2 protein contains two functional domains: an N-terminal transactivation domain (TAD) that is involved in 
transcriptional regulation and direct association with E1, and a C-terminal DNA-binding/dimerization domain (DBD). These domains are 
separated by a hinge region. E2 facilitates recognition of the viral replication origin and helps in the assembly of additional E1 proteins 
into replication competent double hexamers required for bidirectional DNA unwinding. E2 is also implicated in the regulation of viral 
gene transcription and segregation of the viral genome at mitosis. 
 
 
 
Initiation of HPV DNA replication. Replication begins with the recruitment of E1 by E2 to the Ori (which contains of a cluster of three 
E2 binding sites flanking a series of overlapping E1 binding sites) (Chow and Broker, 2013). This recruitment step involves an essential 
protein-protein interaction between the E2 transactivating domain (i.e. TAD) and the E1 helicase domain. In a second step, the E2 
protein recruits additional E1 molecules promoting their assembly into a replication-competent double hexameric helicase. ATP also 
stimulates the oligomerization of E1 and is required for the helicase activity of E1 protein. Finally, the E1 protein interacts with host 
cell replication factors [replication protein A, topoisomerase I and DNA polymerase α primase (pol α)] promoting bidirectional 
replication of the viral genome. Following initiation, the clamp loader, RFC (replication factor C 
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Box 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic representation of high-risk HPV16 E5 (top), E6 (middle) and E7 (bottom) oncoproteins. C: cysteine, L: leucine, E: 
glutamic acid, T: threonine, Q: glutamine, S: serine, X: any amino acid. TM: transmembrane domain, CR: conserved region. E5 is 
a transmembrane protein that functions by inducing ligand-independent dimerization and activation of receptor protein 
tyrosine kinases including epidermal growth factor receptor. E5 oncoprotein may contribute to some early steps of viral 
transformation but it is not necessary for malignant progression and/or maintenance of the transformed phenotype and it is 
generally not expressed in cervical carcinoma. In contrast to E5, the E6 and E7 oncoproteins are consistently expressed in 
cervical carcinomas and maintenance of the transformed state. Both E6 and E7 contain zinc-binding domains consisting of two 
copies of CXXC separated by 29 amino acid residues and they may have evolved from a common ancestor.  
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Box 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Targeting of the tumor suppressor protein p53 via ubiquitination by HPV E6. The best characterized HPV16 E6 
activity is the association with the ubiquitin-protein ligase E6AP (E6 associated protein). The dimeric complex then binds to 
p53 and E6AP catalizes the multi-ubiquitination of p53. (B) Deregulation of the cell cycle restriction point G1/S by HPV E7. 
The E7 protein binds to several cellular factors, being the best characterized of these interactions the association with the 
retinoblastoma (Rb) family of proteins. The Rb family of proteins controls the G1/S phase transition by regulating the 
activity of the E2F family of transcription factors. The transcriptionally active forms of E2F are heterodimers that contain an 
E2F polypeptide (E2F1-8) and a polypeptide encoded by the E2F dimerization partner (DP) gene family (DP-1, DP-2). The 
transcriptional activity of E2F/DP heterodimers is influenced by association with the members of the retinoblastoma (Rb) 
tumor suppressor protein family (pRb, p107, and p130). E2F transcription factors are critical regulators of G1 exit and S-phase 
progression as well as a number of other cellular processes, including cellular differentiation, apoptosis, and genomic instability. The G1 
specific Rb/E2F complex acts as a transcriptional repressor. In quiescent cells, the hypo-phosphorylated form of Rb represses 
transcription of E2F-dependent promoters by directly binding to the E2F transactivation domain. Following exposure to 
mitogenic signals, normal cells activate genes encoding the G1 specific D-type cyclins (i.e. D1, D2, and D3). These cyclins 
associate with a catalytic subunit (i.e. CDK4 or CDK6) and the kinase complexes phosphorylate Rb in mid-G1 phase which 
results in the release of active E2F/DP-1 heterodimer complexes and progression through the restriction point. The binding 
of high-risk E7 to Rb disrupts Rb-E2F complexes, leading to the constitutive expression of E2F-reponsive genes. As a result, 
cells that express E7 can enter the S phase without mitogenic signals.  
 
